

Rh₂(II)-Catalyzed Ring Expansion of Cyclobutanol-substituted Aryl Azides to Access Medium-Sized N-Heterocycles

Wrickban Mazumdar,¹ Navendu Jana,¹ Bryant T. Thurman,¹ Donald J. Wink,¹ and Tom G. Driver^{1,2*}

¹ Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, Illinois, USA, 60607-7061

² Institute of Next Generation Matter Transformation, College of Chemical Engineering, Huaqiao University, 668 Jimei Blvd. Xiamen, Fujian, 361021, P. R. China

Supporting Information

Contents:


I.	Synthesis of <i>ortho</i> -Cyclobutanol Anilines.....	s-2
II.	Synthesis of <i>o</i> -Cyclobutanol Aryl Azides.....	s-15
III.	Rh ₂ (II)-Catalyzed Benzazepine-2-one Formation.....	s-23
IV.	Mechanistic Experiments.....	s-30
V.	References.....	s-33
VI.	Spectral Data.....	s-35

General. ¹H NMR and ¹³C NMR spectra were recorded at ambient temperature using 500 MHz or 300 MHz spectrometers. The data are reported as follows: chemical shift in ppm from internal tetramethylsilane on the d scale, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration. High-resolution mass spectra were obtained by peak matching. Melting points are reported uncorrected. Analytical thin layer chromatography was performed on 0.25 mm silica gel plates with UV254 fluorescent indicator. Liquid chromatography was performed using forced flow (flash chromatography) of the indicated solvent system on 60Å (40 – 60 µm) mesh silica gel (SiO₂). Medium pressure liquid chromatography (MPLC) was performed using pumps to force flow the indicated solvent system down columns that had been packed with 60Å (40 – 60 µm) mesh silica gel (SiO₂). All reactions were carried out under an atmosphere of nitrogen in glassware that was oven-dried. Unless otherwise noted, all reagents were commercially obtained and, where appropriate, purified prior to use. Acetonitrile, methanol, toluene, THF, Et₂O, and CH₂Cl₂ were dried by filtration through alumina according to the procedure of Grubbs.¹ Metal salts were stored in a nitrogen atmosphere dry box.


I. Synthesis of *ortho*-Cyclobutanol Anilines

The *ortho*-cyclobutanol anilines for our method development were constructed from either 2-bromoformamide **s1** or *N*-Boc aniline (Scheme s1).

1. Origin 2-bromoformamide




2. Origin *N*-Boc-aniline



Scheme s1. Strategies to construct the *ortho*-cyclobutanol aniline precursors


A. General Procedure for Formamide Synthesis

The formamides were prepared following the protocol reported by Takemoto and co-workers.²




To a mixture of formic acid (3.49 equiv) and acetic anhydride (1.25 equiv) was added a solution of 2-bromoaniline (1.0 equiv) in CH_2Cl_2 and the mixture was stirred at room temperature. After 2 h, the mixture was concentrated under reduced pressure to afford the formamide product as a solid. No additional purification was performed.


B. Characterization Data of Formamides.




N-(2-Bromophenyl)formamide s1a.³ The general procedure was followed by using 2.00 g of 2-bromoaniline (11.6 mmol), 1.52 mL of formic acid and 1.36 mL of Ac_2O to give the product, a white solid, as a 2:1 mixture of rotamers (2.03 g, 88%). The spectral data of **s1a** matched that reported by Sarvari and Sharghi:³ ^1H NMR (500 MHz, CDCl_3) δ 8.70 (d, $J = 6.0$ Hz, 0.47H), 8.49 (s, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.70 (br s, 1H), 7.60 (d, $J = 8.0$ Hz, 0.52H), 7.55 (dd, $J = 8.0$ Hz, 1.5 Hz, 1H), 7.34 – 7.30 (m, 1.54H), 7.27 – 7.25 (m, 0.69H), 7.07 (t, $J = 8.0$ Hz, 0.5H), 7.02 – 6.99 (m, 1H), only visible signals; ^{13}C NMR (125 MHz, CDCl_3) δ 161.5 (CH), 158.6 (CH), 134.8 (C), 133.5 (CH), 132.4 (CH), 128.7 (CH), 128.5 (CH), 126.4 (CH), 125.7 (CH), 122.3 (CH), 119.0 (CH), 114.5 (C), 113.0 (C), only visible signals; ATR-FTIR (thin film): 3259, 3106, 2906, 1702, 1665, 1577, 1595, 1521, 1466, 1401, 1293, 1158, 1045, 908, 739 cm^{-1} .




N-(2-Bromo-4-methoxyphenyl)formamide s1b. The general procedure was followed by using 2.00 g of 2-bromo-4-methoxy aniline (9.9 mmol), 1.30 mL of formic acid and 1.16 mL of Ac₂O to give the product, a brown solid, as a 2:1 mixture of rotamers (2.03 g, 94%): mp = 115 – 117 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.49 (d, *J* = 11.5 Hz, 0.46H), 8.43 (s, 1H), 8.22 (d, *J* = 9.0 Hz, 1H), 7.44 (br s, 1H), 7.27 – 7.26 (m, 0.67H), 7.17 – 7.16 (m, 1H), 7.11 – 7.10 (m, 1H), 6.87 (dd, *J* = 9.0 Hz, 2.5 Hz, 1.51H), 3.80 (s, 1.47H), 3.79 (s, 3H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 162.1 (C), 159.0 (CH), 156.7 (C), 128.1 (C), 123.5 (CH), 121.8 (CH), 118.5 (CH), 117.7 (CH), 114.5 (CH), 113.9 (CH), 55.8 (CH₃) 55.7 (CH₃), only visible signals; ATR-FTIR (thin film): 3247, 2891, 1697, 1662, 1581, 1538, 1488, 1403, 1393, 1294, 1223, 1032, 872, 837, 724 cm⁻¹. HRMS (ESI) m/z calcd for C₈H₉NO₂Br [M + H]⁺: 229.9816, found 229.9817.



N-(2-Bromo-4-methylphenyl)formamide s1c.⁴ The general procedure was followed by using 1.00 g of 2-bromo-4-methyl aniline (5.4 mmol), 0.71 mL of formic acid and 0.63 mL of Ac₂O to give the product, a brown solid, as a 2:1 mixture of rotamers (1.2 g, quantitative). The spectral data of s1c matched that reported by Heinicke and co-workers:⁴ ¹H NMR (500 MHz, CDCl₃) δ 8.62 (d, *J* = 11.5 Hz, 0.49H), 8.46 (s, 1H), 8.23 (d, *J* = 8.5 Hz, 1H), 7.59 (br s, 1H), 7.42 (s, 0.49H), 7.37 (s, 1H), 7.13 (t, *J* = 10.0 Hz, 2H), 2.32 (s, 1.65H), 2.30 (s, 3H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 161.8 (CH), 158.8 (CH), 136.8 (C), 135.8 (C), 133.8 (CH), 132.6 (CH), 132.5 (C), 132.3 (C), 129.3 (CH), 129.1 (CH), 122.2 (CH), 119.4 (CH), 114.7 (C), 113.0 (C), 20.6 (CH₃), 20.5 (CH₃), only visible signals; ATR-FTIR (thin film): 3242, 2905, 1694, 1666, 1574, 1505, 1399, 1224, 1038, 863, 816, 732, 672 cm⁻¹.




N-(2-Bromo-4-trifluoromethylphenyl)formamide s1d. The general procedure was followed by using 0.894 g of 2-bromo-4-trifluoromethyl aniline (5.40 mmol), 0.49 mL of formic acid and 0.43 mL of Ac₂O to give the product, a white solid, as a mixture of rotamers (0.972 g, 97%): mp = 101 – 103 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.83 (d, *J* = 10.0 Hz, 0.24H), 8.58 (d, *J* = 8.5 Hz, 1H), 8.55 (s, 1H), 7.87 (s, 0.41H), 7.82 (s, 2H), 7.59 (d, *J* = 8.5 Hz, 1H), 7.36 (d, *J* = 8.0 Hz, 0.22H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 160.7 (CH), 158.9 (CH), 137.8 (C), 130.8 (C), 129.5 (CH), 127.5 (C), 127.3 (C), 125.9 (CH), 125.8 (CH), 123.0 (q, *J*_{CF} = 278.4 Hz, C), 121.7 (CH), 117.5 (C), 112.2 (C), only visible signals; ¹⁹F NMR (282 MHz, CDCl₃) δ -62.8; ATR-FTIR (thin film): 3278, 1705, 1609, 1525, 1397, 1321, 1265, 1120, 1077, 894, 821, 734, 677 cm⁻¹. HRMS (ESI) m/z calcd for C₈H₆NOF₃Br [M + H]⁺: 267.9587, found 267.9585.




N-(2-Bromo-4-trifluoromethoxyphenyl)formamide s1e. The general procedure was followed by using 1.00 g of 2-bromo-4-trifluoromethoxy aniline (3.91 mmol), 0.51 mL of formic acid and 0.46 mL of Ac₂O to give the product, a white solid, as a mixture of rotamers (1.12 g, quantitative): mp = 110 – 112 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.67 (d, *J* = 10.5 Hz, 0.26 H), 8.50 (d, *J* = 1.0 Hz, 1H), 8.45 (d, *J* = 9.5 Hz, 1H), 7.69 (br s, 1H), 7.51 (s, 0.26H), 7.45 (d, *J* = 2.0 Hz, 1H), 7.29 (d, *J* = 9.0 Hz, 0.26H), 7.21 (d, *J* = 7.5 Hz, 1.3H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 161.3 (CH), 158.8 (CH), 145.1 (C), 133.8 (C), 126.4 (CH), 125.2 (CH), 122.7 (CH), 122.4 (q, *J*_{CF} = 256.5 Hz, C), 121.5 (CH), 121.2

(CH), 119.6 (CH), 114.7 (C), 112.9 (C), only visible signals; ^{19}F NMR (282 MHz, CDCl_3) δ -58.7; ATR-FTIR (thin film): 3190, 3034, 2894, 1659, 1541, 1482, 1396, 1294, 1197, 1163, 1040, 942, 888, 849, 709 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_8\text{H}_6\text{NO}_2\text{BrF}_3$ [M + H] $^+$: 285.9535, found 285.9534.




N-(2-Bromo-5-methylphenyl)formamide s1g. The general procedure was followed by using 1.00 g of 2-bromo 5-methyl aniline (5.37 mmol), 0.71 mL of formic acid and 0.63 mL of Ac_2O to give the product, a brown solid, as a 2:1 mixture of rotamers (1.24 g, quantitative): mp = 97 – 99 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.69 (d, J = 11.0 Hz, 0.51H), 8.47 (s, 1H), 8.22 (s, 1H), 7.63 (br s, 1.33H), 7.45 (d, J = 8.0 Hz, 0.53H), 7.41 (d, J = 8.0 Hz, 1H), 7.07 (s, 0.49H), 6.88 (d, J = 8.0 Hz, 0.53H), 6.62 (d, J = 8.0 Hz, 1H), 2.33 (s, 1.62H), 2.32 (s, 3.34 H) only visible signals; ^{13}C NMR (125 MHz, CDCl_3) δ 161.5 (CH), 158.8 (CH), 138.8 (C), 134.4 (C), 133.1 (CH), 131.9 (CH), 127.3 (CH), 126.6 (CH), 122.8 (CH), 119.7 (CH), 109.7 (C), 21.3 (CH_3), 21.1 (CH_3), only visible signals; ATR-FTIR (thin film): 3239, 2922, 1652, 1581, 1526, 1411, 1291, 1195, 1030, 815, 718, 701 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_8\text{H}_9\text{NOBr}$ [M + H] $^+$: 213.9870, found 213.9868.




N-(2-Bromo-5-fluorophenyl)formamide s1h. The general procedure was followed by using 1.00 g of 2-bromo-5-fluoro aniline (5.30 mmol), 0.70 mL of formic acid and 0.62 mL of Ac_2O to give the product, a white solid, as a 4:1 mixture of rotamers (1.05 g, 88%): mp = 133 – 135 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.72 (d, J = 11.0 Hz, 0.25H), 8.50 (s, 1H), 8.28 (dd, J = 10.5 Hz, 2.5 Hz, 1H), 7.70 (br s, 1H), 7.57 – 7.54 (m, 0.29H), 7.50 (dd, J = 8.5 Hz, 5.5 Hz, 1H), 7.01 (d, J = 9.0 Hz, 0.25H), 6.81 (t, J = 8.5 Hz, 0.28H), 6.76 (ddd, J = 11.0 Hz, 8.5 Hz, 3.0 Hz, 1H), only visible signals; ^{13}C NMR (125 MHz, CDCl_3) δ 163.1 (C), 161.1 (d, J_{CF} = 31.4 Hz, C), 158.8 (CH), 137.0 (C), 136.0 (d, J_{CF} = 11.4 Hz, C), 134.4 (d, J_{CF} = 9.4 Hz, C), 133.0 (d, J_{CF} = 9.0 Hz, CH), 113.2 (d, J_{CF} = 23.3 Hz, C), 112.6 (d, J_{CF} = 23.4 Hz, CH), 109.7 (d, J_{CF} = 28.3 Hz, CH), 106.7 (d, J_{CF} = 3.6 Hz, C), 106.0 (d, J_{CF} = 27.3 Hz, C), only visible signals; ^{19}F NMR (282 MHz, CDCl_3) δ -111.2; ATR-FTIR (thin film): 3261, 3107, 2907, 1668, 1608, 1541, 1427, 1398, 1280, 1133, 1101, 1032, 866, 795, 612 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_7\text{H}_6\text{NOFBr}$ [M + H] $^+$: 217.9615, 217.9617 found.



N-(2-Bromo-5-trifluoromethylphenyl)formamide s1i. The general procedure was followed by using 1.00 g of 2-bromo-5-trifluoromethyl aniline (4.20 mmol), 0.56 mL of formic acid and 0.50 mL of Ac_2O to give the product, a white solid, as a mixture of rotamers (0.916 g, 91%): mp = 96 – 98 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.78 (s, 0.15H), 8.74 (s, 1H), 8.54 (s, 1H), 7.85 (br s, 1H), 7.74 (d, J = 7.5 Hz, 0.29H), 7.68 (d, J = 8.0 Hz, 1H), 7.50 (s, 0.23H), 7.32 (d, J = 8.0 Hz, 0.24H), 7.25 (d, J = 6.0 Hz, 0.85H), only visible signals; ^{13}C NMR (125 MHz, CDCl_3) δ 161.0 (CH), 158.9 (CH), 135.4 (C), 134.2 (CH), 132.9 (CH), 131.0 (q, J_{CF} = 32.6 Hz, C), 123.4 (q, J_{CF} = 269.9 Hz, C), 122.7 (CH), 122.0 (q, J_{CF} = 4.1 Hz, CH), 118.8 (q, J_{CF} = 4.5 Hz, CH), 116.3 (C), 115.1 (CH), only visible signals; ^{19}F NMR (282 MHz, CDCl_3) δ -63.3; ATR-FTIR (thin film): 3289, 2894, 1677, 1586, 1524, 1427, 1325, 1236, 1169, 1119, 1078, 1029, 894, 819, 737 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_8\text{H}_6\text{NOF}_3\text{Br}$ [M + H] $^+$: 267.9586, found 267.9585.




N-(2-Bromo-5-fluoro-4-methylphenyl)formamide s1j. The general procedure was followed by using 0.900 g of 2-bromo 5-fluoro 4-methyl aniline (4.20 mmol), 0.58 mL of formic acid and 0.52 mL of Ac₂O to give the product, a brown solid, as a mixture of rotamers (1.02 g, quantitative): mp = 108 – 110 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.64 (d, *J* = 11.0 Hz, 0.29H), 8.45 (d, *J* = 1.0 Hz, 1H), 8.16 (d, *J* = 11.5 Hz, 1H), 7.69 (br s, 1H), 7.41 (d, *J* = 7.5 Hz, 0.28H), 7.34 (d, *J* = 7.5 Hz, 1H), 6.95 (d, *J* = 10.0 Hz, 0.28H), 2.23 (s, 1H), 2.21 (d, *J* = 1.5 Hz, 3.4H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 161.3 (CH), 160.2 (d, *J*_{CF} = 243.1 Hz, C), 158.8 (CH), 135.3 (d, *J*_{CF} = 6.4 Hz, CH), 133.9 (d, *J*_{CF} = 6.0 Hz, CH), 133.4 (d, *J*_{CF} = 11.4 Hz, C), 122.6 (d, *J*_{CF} = 19.1 Hz, C), 109.4 (d, *J*_{CF} = 30.1 Hz, CH), 106.4 (d, *J*_{CF} = 3.4 Hz, C), 106.3 (CH), 106.1 (CH), 14.0 (CH₃), 13.9 (CH₃); ¹⁹F NMR (282 MHz, CDCl₃) δ -118.7, -115.2; ATR-FTIR (thin film): 3241, 2906, 1697, 1668, 1619, 1514, 1502, 1405, 1294, 1197, 1170, 1120, 877, 772, 749, 602 cm⁻¹. HRMS (ESI) m/z calcd for C₈H₈NOFBr [M + H]⁺: 231.9776, found 231.9773.



N-(2-Bromo-6-methoxyphenyl)formamide s1k: The general procedure was followed by using 1.00 g of 2-bromo 6-methoxy aniline (4.50 mmol), 0.65 mL of formic acid and 0.58 mL of Ac₂O to give the product, a brown solid, as a mixture of rotamers (1.13 g, quantitative): mp = 110 – 112 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, *J* = 11.0 Hz, 0.39H), 8.40 (br s, 0.12H), 7.27 – 7.25 (m, 0.15H), 7.22 (d, *J* = 8.0 Hz, 0.56H), 7.14 (br s, 0.19H), 7.07 (t, *J* = 9.0 Hz, 0.65H), 7.03 (d, *J* = 8.5 Hz, 0.50H), 6.92 (d, *J* = 8.0 Hz, 0.65H), 6.72 (d, *J* = 8.5 Hz, 0.39H), 6.60 – 6.57 (m, 0.38H), 4.20 (s, 0.67H), 3.85 (d, *J* = 5.5Hz, 2.96H), only visible signals; ¹³C NMR (125 MHz, CDCl₃) δ 164.5 (C), 164.0 (C), 150.0 (C), 127.4 (CH), 125.2 (CH), 124.3 (CH), 118.1 (CH), 111.0 (CH), 109.0 (CH), 108.6 (C), 56.2 (CH₃), 55.9 (CH₃); ATR-FTIR (thin film): 3247, 2891, 1697, 1662, 1581, 1538, 1488, 1403, 1393, 1294, 1223, 1032, 872, 837, 724 cm⁻¹. HRMS (ESI) m/z calcd for C₈H₉NO₂Br [M + H]⁺: 229.9819, found 229.9817.

C. General Procedure for Synthesis of *o*-Cyclobutanol Anilines from 2-Bromoformamides

The *o*-cyclobutanol formamides were prepared following the protocol reported by Curtin and co-workers.⁵ The formyl group was removed through a base-mediated hydrolysis reaction to provide the *o*-cyclobutanol aniline.




To a slurry of NaH (60% dispersion in mineral oil, 1.83 equiv) in THF (6 mL was added dropwise a solution of *N*-(2-bromophenyl) formamide (1.0 equiv) in 4 mL of tetrahydrofuran. The mixture was stirred at room temperature for 20 minutes, then chilled to – 78 °C. To the cold suspension was added dropwise a 2.5 M solution of *n*-butyllithium in hexanes (1.25 equiv). The mixture was stirred at – 78 °C. After 30 minutes, cyclobutanone (1.1 equiv) was added dropwise. The mixture was stirred at – 78 °C. After 2 hours, the reactives were quenched by adding 20 mL of a saturated aqueous solution of NH₄Cl. The resulting mixture was warmed to room temperature. The mixture was extracted with 3 × 30 mL of ethyl acetate, and the combined organic layers were dried over Na₂SO₄, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by medium pressure liquid chromatography

(MPLC) to give the title compounds as a mixture of rotational isomers, which were submitted to the next step without characterization.

The mixture of *o*-cyclobutanol formamide rotamers was dissolved in dioxane and treated with a 5% aq soln of KOH. The resulting mixture was heated to reflux, and the reaction progress was monitored using thin layer chromatography until the starting material was completely consumed. After the reaction mixture was cooled to room temperature, it was diluted with water. The resulting mixture was extracted with 3 × 10 mL of EtOAc. The combined organic extracts were washed with brine, dried over MgSO₄ and the filtrate was concentrated under reduced pressure. The resulting residue was purified by MPLC to afford the product.

D. Characterization Data of *o*-Cyclobutanol Formamides




N-(2-(1-Hydroxycyclobutyl)phenyl)formamide s2a. The general procedure was followed by using 0.653 g (17.0 mmol) of NaH, 2.00 g (9.30 mmol) of **s1a**, 4.65 mL (11.6 mmol) of *n*-BuLi and 0.760 mL (10.2 mmol) of cyclobutanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) provided **s2a** as a thick yellow oil (0.50 g, 26%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(2-(1-Hydroxycyclobutyl)phenyl)aniline s3a.⁵ The general procedure was followed by using 0.200 g (1.23 mmol) of **s2a**. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.083 g, 50%): **s3a** was previously reported by Curtin and co-workers:⁵ R_f = 0.28 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃ with 1% (v/v) TMS) δ 7.23 (dd, J = 7.5 Hz, 1.0 Hz, 1H), 7.12 – 7.09 (m, 1H), 6.74 (dt, J = 7.5 Hz, 1.5 Hz, 1H), 6.69 (dd, J = 8.0 Hz, 1.5 Hz, 1H), 4.19 (br s, 2H), 2.70 – 2.65 (m, 2H), 2.39 – 2.33 (m, 2H), 2.04 – 1.96 (m, 1H), 1.69 – 1.60 (m, 1H); ¹³C NMR (125 MHz, CDCl₃ with 1% (v/v) TMS) δ 145.6 (C), 128.8 (CH), 128.1 (C), 125.3 (CH), 117.7 (CH), 116.8 (CH), 77.6 (C), 35.1 (CH₂), 13.7 (CH₂); ATR-FTIR (thin film): 3341, 2925, 2853, 1608, 1494, 1456, 1303, 1122, 746 cm⁻¹.




N-(2-(1-Hydroxycyclobutyl)-4-methoxyphenyl)formamide s2b. The general procedure was followed by using 0.303 g (7.90 mmol) of NaH, 1.00 g (4.30 mmol) of **s1b**, 2.20 mL (5.40 mmol) of *n*-BuLi and 0.350 mL (4.70 mmol) of cyclobutanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick yellow oil (0.20 g, 21%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(2-(1-Hydroxycyclobutyl)-4-methoxyphenyl)aniline s3b. The general procedure was followed by using 0.300 g (1.30 mmol) of **s2b**. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.280 g, 78%): R_f = 0.13 (5:1 hexanes:EtOAc); mp = 121 – 123 °C; ¹H NMR (500 MHz, CDCl₃) δ 6.84 – 6.83 (m, 1H), 6.70 – 6.67 (m, 1H), 6.64 – 6.62 (m, 1H), 3.85 – 3.75 (m, 5H), 2.64 – 2.59 (m, 2H), 2.38 – 2.31 (m, 2H), 2.02 – 1.95 (m, 1H), 1.69 – 1.60 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 152.3 (C), 138.9 (C), 130.5 (C), 118.0 (CH), 113.1 (CH), 112.3 (CH), 77.3 (C), 55.9 (CH₃), 35.1 (CH₂), 13.6 (CH₂); ATR-FTIR (thin film): 3400, 3363, 2935, 1766, 1498, 1428, 1286, 1217, 1128, 1048, 815 cm⁻¹. HRMS (EI) m/z calcd for C₁₁H₁₅NO₂: 193.1103, found 193.1094.




N-(2-(1-Hydroxycyclobutyl)-4-methylphenyl)formamide s2c. The general procedure was followed by using 0.164 g (4.30 mmol) of NaH, 0.500 g (2.34 mmol) of **s1c**, 1.20 mL (2.93 mmol) of *n*-BuLi and 0.200 mL (4.70 mmol) of cyclohexanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.10 g, 20%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(2-(1-Hydroxycyclobutyl)-4-methylphenyl)aniline s3c. The general procedure was followed by using 0.250 g (1.22 mmol) of **s2c**. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.130 g, 60%): R_f = 0.18 (5:1 hexanes:EtOAc); mp = 104 – 106 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.02 (s, 1H), 6.93 (d, *J* = 7.5 Hz, 1H), 6.60 (d, *J* = 8.0 Hz, 1H), 3.98 (br s, 2H), 2.67 – 2.62 (m, 2H), 2.36 – 2.31 (m, 2H), 2.27 (s, 3H), 2.02 – 1.97 (m, 1H), 1.68 – 1.60 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 142.9 (C), 129.1 (CH), 128.6 (C), 127.0 (C), 125.9 (CH), 117.1 (CH), 77.5 (C), 35.1 (CH₂), 20.7 (CH₃), 13.8 (CH₂); ATR-FTIR (thin film): 3367, 2983, 2945, 2860, 1502, 1319, 1290, 1130, 909, 815, 760 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₄NO [M – H]⁺: 176.1073, found 176.1075.



N-(2-(1-Hydroxycyclobutyl)-4-trifluoromethylphenyl)formamide s2d. The general procedure was followed by using 0.211 g (5.50 mmol) of NaH, 0.800 g (3.00 mmol) of **s1d**, 1.50 mL (3.80 mmol) of *n*-BuLi and 0.250 mL (3.30 mmol) of cyclohexanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.20 g, 26%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.


N-(2-(1-Hydroxycyclobutyl)-4-trifluoromethylphenyl)aniline s3d. The general procedure was followed by using 0.260 g (1.00 mmol) of **s2d**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a yellow solid (0.160 g, 70%): R_f = 0.33 (5:1 hexanes:EtOAc), mp = 107 – 109 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.42 (s, 1H), 7.33 (d, *J* = 8.5 Hz, 1H), 6.67 (d, *J* = 8.0 Hz, 1H), 4.16 (br s, 2H), 2.65 – 2.60 (m, 2H), 2.37 – 2.31 (m, 2H), 2.04 – 1.96 (m, 1H), 1.68 – 1.59 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 148.7 (C), 127.3 (C), 126.0 (q, *J*_{CF} = 4.0 Hz, CH), 124.8 (q, *J*_{CF} = 268.5 Hz, C), 122.6 (q, *J*_{CF} = 3.3 Hz, CH), 118.9 (q, *J*_{CF} = 32.0 Hz, C), 115.9 (CH), 77.3 (C), 34.9 (CH₂), 13.6 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -61.4 ; ATR-FTIR (thin film): 3374, 3203, 2992, 2954, 1622, 1331, 1263, 1176, 1110, 1082, 904 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₁NOF₃ [M – H]⁺: 230.0799, found 230.0793.



N-(2-(1-Hydroxycyclobutyl)-4-trifluoromethoxyphenyl)formamide s2e. The general procedure was followed by using 0.246 g (6.40 mmol) of NaH, 1.00 g (3.50 mmol) of **s1e**, 1.80 mL (3.80 mmol) of *n*-BuLi and 0.290 mL (3.30 mmol) of cyclohexanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.29 g, 30%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.


N-(2-(1-Hydroxycyclobutyl)-4-trifluoromethoxyphenyl)aniline s3e. The general procedure was followed by using 0.300 g (1.09 mmol) of **s2e**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a yellow solid (0.180 g, 65%): R_f = 0.25 (5:1 hexanes:EtOAc); mp = 116 – 118 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.06 (d, *J* = 2.0 Hz, 1H), 6.98 –

6.96 (m, 1H), 6.61 (d, $J = 9.0$ Hz, 1H), 4.26 (br s, 2H), 2.62 – 2.57 (m, 2H), 2.37 – 2.31 (m, 2H), 2.03 – 1.95 (m, 1H), 1.67 – 1.58 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 144.4 (C), 140.6 (C), 129.0 (C), 121.6 (CH), 120.7 (q, $J_{\text{CF}} = 253.6$ Hz, C), 118.8 (CH), 117.0 (CH), 77.1 (C), 35.0 (CH_2), 13.5 (CH_2); ^{19}F NMR (282 MHz, CDCl_3) δ –58.8; ATR-FTIR (thin film): 3375, 2990, 1625, 1498, 1249, 1215, 1154, 885, 822 cm^{-1} . HRMS (EI) m/z calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_2\text{F}_3$: 247.0813, found 247.0820.




N-(2-(1-Hydroxycyclobutyl))-5-methylphenyl)formamide s2g. The general procedure was followed by using 0.329 g (8.55 mmol) of NaH, 1.00 g (4.67 mmol) of **s1g**, 2.30 mL (5.84 mmol) of *n*-BuLi and 0.390 mL (5.14 mmol) of cyclobutanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.20 g, 21%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(2-(1-Hydroxycyclobutyl)-5-methylphenyl)aniline s3g. The general procedure was followed by using 0.180 g (1.02 mmol) of **s2g**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a brown solid (0.16 g, 75%): $R_f = 0.28$ (5:1 hexanes:EtOAc); mp = 96 – 98 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.10 (d, $J = 8.0$ Hz, 1H), 6.56 (d, $J = 8.0$ Hz, 1H), 6.51 (s, 1H), 4.12 (br s, 2H), 2.66 – 2.61 (m, 2H), 2.34 (q, $J = 9.0$ Hz, 2H), 2.27 (s, 3H), 2.01 – 1.93 (m, 1H), 1.62 (quin, $J = 8.5$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 145.5 (C), 138.6 (C), 125.7 (C), 125.3 (CH), 118.5 (CH), 117.6 (CH), 77.2 (C), 35.1 (CH_2), 21.1 (CH_3), 13.7 (CH_2); ATR-FTIR (thin film): 3418, 3320, 2976, 2934, 2858, 1615, 1510, 1428, 1115, 819, 792 cm^{-1} . HRMS (EI) m/z calcd for $\text{C}_{11}\text{H}_{15}\text{NO}$: 177.11541, found 177.11537.



N-(5-Fluoro-2-(1-hydroxycyclobutyl)phenyl)formamide s2h. The general procedure was followed by using 0.288 g (7.50 mmol) of NaH, 0.900 g (4.10 mmol) of **s1h**, 2.00 mL (5.10 mmol) of *n*-BuLi and 0.340 mL (4.50 mmol) of cyclobutanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.15 g, 18%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(5-Fluoro-2-(1-hydroxycyclobutyl)phenyl)aniline s3h. The general procedure was followed by using 0.215 g (1.03 mmol) of **s2h**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a brown solid (0.130 g, 68%): $R_f = 0.25$ (5:1 hexanes:EtOAc); mp = 139 – 141 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.11 (dd, $J = 8.0$ Hz, 6.0 Hz, 1H), 6.38 (dt, $J = 8.5$ Hz, 2.5 Hz, 1H), 6.33 (dd, $J = 11.0$ Hz, 2.5 Hz, 1H), 4.30 (br s, 2H), 2.60 – 2.55 (m, 2H), 2.32 – 2.27 (m, 2H), 2.00 – 1.92 (m, 1H), 1.64 – 1.55 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.0 (d, $J_{\text{CF}} = 240.8$ Hz, C), 147.5 (d, $J_{\text{CF}} = 9.4$ Hz, C), 126.7 (d, $J_{\text{CF}} = 11.0$ Hz, CH), 124.0 (C), 103.7 (d, $J_{\text{CF}} = 20.3$ Hz, CH), 103.2 (d, $J_{\text{CF}} = 24.0$ Hz, CH), 77.1 (C), 35.2 (CH_2), 13.7 (CH_2); ^{19}F NMR (282 MHz, CDCl_3) δ –115.2; ATR-FTIR (thin film): 3418, 3326, 3230, 2923, 2852, 1622, 1434, 1332, 1162, 1126, 1104, 870, 804, 740 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{10}\text{H}_{11}\text{NOF}$ [M – H] $^+$: 180.0827, found 180.0825.




N-(2-(1-Hydroxycyclobutyl)-5-trifluoromethylphenyl)formamide s2i. The general procedure was followed by using 0.209 g (5.45 mmol) of NaH, 0.800 g (2.98 mmol) of **s1i**, 1.50 mL (3.73 mmol) of *n*-BuLi and 0.250 mL (3.30 mmol) of cyclohexanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.18 g, 23%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(2-(1-Hydroxycyclobutyl)-5-trifluoromethylphenyl)aniline s3i. The general procedure was followed by using 0.263 g (1.02 mmol) of **s2i**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a yellow solid (0.170 g, 70%): R_f = 0.28 (5:1 hexanes:EtOAc); mp = 102 – 104 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.26 (d, *J* = 8.0 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 1H), 6.86 (s, 1H), 4.40 (s, 2H), 2.64 – 2.59 (m, 2H), 2.37 – 2.31 (m, 2H), 2.02 – 1.96 (m, 1H), 1.65 – 1.58 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 146.0 (C), 130.9 (q, *J*_{CF} = 31.9 Hz, C), 127.4 (C), 125.7 (CH), 124.1 (q, *J*_{CF} = 270.5 Hz, C), 114.0 (q, *J*_{CF} = 4.0 Hz, CH), 112.9 (q, *J*_{CF} = 3.6 Hz, CH), 77.2 (C), 35.0 (CH₂), 13.6 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ –63.3; ATR-FTIR (thin film): 3418, 3326, 3230, 2923, 2852, 1622, 1434, 1332, 1162, 1126, 1104, 870, 804, 740 cm^{–1}. HRMS (ESI) m/z calcd for C₁₁H₁₁NOF₃ [M – H]⁺: 230.0783, found 230.0793.



N-(5-Fluoro-2-(1-hydroxycyclobutyl)-3-methylphenyl)formamide s2j. The general procedure was followed by using 0.174 g (7.10 mmol) of NaH, 0.900 g (3.90 mmol) of **s1j**, 1.90 mL (4.88 mmol) of *n*-BuLi and 0.320 mL (4.30 mmol) of cyclohexanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick brown oil (0.18 g, 21%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.

N-(5-Fluoro-2-(1-hydroxycyclobutyl)-4-methylphenyl)aniline s3j. The general procedure was followed by using 0.260 g (1.17 mmol) of **s2j**. Purification by MPLC (5:1 hexanes:EtOAc) afforded the product as a red solid (0.14 g, 60%) as a mixture of rotamers: R_f = 0.33 (5:1 hexanes:EtOAc); mp = 114 – 116 °C; ¹H NMR (500 MHz, CDCl₃) δ 6.97 (d, *J* = 8.5 Hz, 1H), 6.84 (t, *J* = 8.0 Hz, 0.26H), 6.35 (d, *J* = 11.0 Hz, 1.21H), 4.13 (s, 2H), 2.82 – 2.76 (m, 0.58H), 2.63 – 2.60 (m, 2H), 2.44 – 2.40 (m, 0.70H), 2.35 – 2.29 (m, 3H), 2.16 (s, 3H), 2.12 (s, 0.90 H), 2.00 – 1.96 (m, 1H), 1.88 – 1.85 (m, 0.37H), 1.66 – 1.57 (m, 1H), 1.27 – 1.24 (m, 0.19H); ¹³C NMR (125 MHz, CDCl₃) δ 161.2 (d, *J*_{CF} = 241.3 Hz, C), 145.0 (d, *J*_{CF} = 10.0 Hz, C), 130.3 (d, *J*_{CF} = 8.1 Hz, CH), 128.1 (d, *J*_{CF} = 6.9 Hz, CH), 124.0 (C), 112.6 (d, *J*_{CF} = 17.3 Hz, C), 111.8 (CH), 103.4 (d, *J*_{CF} = 25.0 Hz, CH), 77.1 (C), 37.1 (d, *J*_{CF} = 5.6 Hz, CH₂), 35.3 (CH₂), 17.0 (CH₂), 13.8 (CH₃), 13.7 (CH₂), only visible signals; ¹⁹F NMR (282 MHz, CDCl₃) δ –120.0, –119.2; ATR-FTIR (thin film): 3346, 2948, 2867, 1632, 1587, 1509, 1419, 1310, 1141, 1110, 1044, 1023, 882, 782 cm^{–1}. HRMS (ESI) m/z calcd for C₁₁H₁₃NOF [M – H]⁺: 194.0979, found 194.0981.




N-(2-(1-Hydroxycyclobutyl)-6-methoxyphenyl)formamide s2k. The general procedure was followed by using 0.303 g (7.90 mmol) of NaH, 1 g (4.30 mmol) of **s1k**, 2.20 mL (5.40 mmol) of *n*-BuLi and 0.350 mL (4.70 mmol) of

cyclobutanone to give the crude material. Purification by MPLC (hexanes:EtOAc 3:1– 1:1) gave the product as a thick yellow oil (0.14 g, 13%), which was submitted to the KOH-mediated hydrolysis step without additional characterization.


N-(2-(1-Hydroxycyclobutyl-6-methoxy)phenyl)aniline s3k. The general procedure was followed by using 0.225 g (1.02 mmol) of **s2k**. Purification by MPLC (5:1 hexane:EtOAc) afforded the product as a red solid (0.14 g, 70%): $R_f = 0.25$ (5:1 hexanes:EtOAc); mp = 116 – 118 °C; ^1H NMR (500 MHz, CDCl_3) δ 6.90 (dd, $J = 8.0$ Hz, 1.0 Hz, 1H), 6.79 (dd, $J = 8.0$ Hz, 1.0 Hz, 1H), 6.70 (t, $J = 8.0$ Hz, 1H), 4.36 (s, 2H), 3.86 (s, 3H), 3.85 (s, 1H), 2.70 – 2.65 (m, 2H), 2.40 – 2.31 (m, 2H), 2.02 – 1.95 (m, 1H), 1.68 – 1.59 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 147.8 (C), 135.0 (C), 128.4 (C), 117.6 (CH), 116.7 (CH), 109.9 (CH), 77.6 (C), 55.7 (CH_3), 35.2 (CH_2), 13.8 (CH_2); ATR-FTIR (thin film): 3478, 3389, 3267, 2985, 2942, 2835, 1615, 1568, 1463, 1439, 1284, 1219, 1122, 1048, 954, 837, 734 cm^{-1} . HRMS (EI) m/z calcd for $\text{C}_{11}\text{H}_{15}\text{NO}_2$: 193.10965, found 193.11028.

E. General Procedure for Synthesis of Cyclobutanones



(1*R*,8*S*)-10,10 dichlorobicyclo[6.2.0]decane-9-one **s6.**⁶ The compound was prepared using the procedure developed by Deprés and co-workers.⁶ To a stirred mixture of 0.500 g (4.50 mmol) of commercially available cis-cyclooctene and 0.589 g (9.00 mmol) of Zn-Cu couple under argon was added over 1 h a solution of 0.64 mL (6.80 mmol) of POCl_3 and 0.76 mL (6.80 mmol) of CCl_3COCl in 10 mL dry ether. After the reaction was stirred for 14 h, the ether solution was separated from the excess couple and added to hexane, and the resulting mixture was partially concentrated under reduced pressure in order to precipitate the zinc chloride. The supernatant was decanted and washed successively with cold water, cold aqueous sodium bicarbonate solution, water, and brine, and then dried over anhydrous MgSO_4 . Evaporation of the solvent under reduced pressure afforded **s6** as a clear oil (0.460 g, 45%) which was submitted in the next step without further characterization.

(1*S*,8*S*)-[6.2.0]decane-9-one **s7.**⁷ Dechlorination was accomplished following the procedure developed by Montaigne and Ghosez.⁷ Under an inert atmosphere of argon, 1.60 mL (5.80 mmol) of freshly distilled Bu_3SnH was heated at reflux. To this solution was added, 0.010 g (0.06 mmol) of AIBN and 0.460 g (2.00 mmol) of **s6** in cyclohexane quickly in one portion and refluxed for 1 h. The solution was cooled, concentrated *in vacuo* and purified using MPLC (25:1 hexanes:EtOAc) to give the product as a colorless oil (0.128 g, 42%): $R_f = 0.47$ (10:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 3.29 – 3.21 (m, 1H), 3.14 – 3.08 (m, 1H), 2.53 – 2.43 (m, 2H), 1.81 – 1.62 (m, 5H), 1.59 – 1.53 (m, 3H), 1.40 – 1.23 (m, 4H); ^{13}C NMR (125 MHz, CDCl_3) δ 213.2 (C), 62.4 (CH), 52.4 (CH_2), 30.3 (CH_2), 29.8 (CH), 29.7 (CH_2), 28.6 (CH_2), 26.1 (CH_2), 25.4 (CH_2), 22.0 (CH₂); ATR-FTIR (thin film): 2916, 2850, 1773, 1464, 1445, 1208, 1083 cm^{-1} . HRMS (EI) m/z calcd for $\text{C}_{10}\text{H}_{15}\text{O}$: 151.11177, found 151.11230.




Benzyl 2-(2*R*,3*R*)-2,3-dipropylcyclobutylideneacetate **s8.**⁸ The compound was prepared using the procedure developed by Snider and Spindell.⁸ 0.50 mL (3.20 mmol) of commercially available cis-4 octene was added dropwise to a solution of 0.507 g (2.91 mmol) of benzyl buta-2,3-dienoate and 2.65 mL (2.65 mmol) of EtAlCl_2 in 6 mL of CH_2Cl_2 . The reaction mixture was stirred for 24 h at 25 °C, diluted with ether, and quenched by slow addition of saturated NaH_2PO_4 solution. A 10% aq soln of hydrochloric acid was added to dissolve the precipitated alumina. The two layers were separated and the aqueous layer was washed with three portions of ether. The combined organic layers were dried over MgSO_4 and

concentrated *in vacuo* and purified using MPLC (20:1 hexanes:EtOAc) to give **s8**, a yellow oil, as 12.5:1 (E:Z) mixture of diastereomers (0.641 g, 77%): $R_f = 0.81$ (10:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.38 – 7.29 (m, 5.66H), 5.70 – 5.59 (m, 1H), 5.63 – 5.62 (m, 0.08H), 5.14 (s, 2.06H), 5.13 (s, 0.20H), 3.16 – 3.10 (m, 1.08H), 3.07 – 3.01 (m, 1.09H), 2.73 – 2.68 (m, 1.14H), 2.45 – 2.38 (m, 1.15H), 1.50 – 1.43 (m, 3.27H), 1.39 – 1.18 (m, 6.07H), 0.93 – 0.88 (m, 6.71H), 0.87 (t, $J = 7.5$ Hz, 0.43H); ^{13}C NMR (125 MHz, CDCl_3) δ 171.6 (C), 166.5 (C), 136.5 (C), 128.5 (CH), 128.3 (CH), 128.1 (CH), 128.0 (CH), 111.5 (CH), 111.0 (CH), 65.5 (CH₂), 48.4 (CH), 47.3 (CH), 37.8 (CH₂), 37.6 (CH₂), 34.4 (CH), 34.2 (CH), 32.6 (CH₂), 32.1 (CH₂), 30.9 (CH₂), 30.0 (CH₂), 22.0 (CH₂), 21.3 (CH₂), 20.7 (CH₂), 14.4 (CH₃), 14.2 (CH₃), 14.2 (CH₃); ATR-FTIR (thin film): 2956, 2927, 2871, 1714, 1670, 1456, 1377, 1336, 1260, 1176, 1004 cm^{-1} . HRMS (EI) m/z calcd for $\text{C}_{19}\text{H}_{26}\text{O}_2$: 286.19366, found 286.19328.

(2*R*,3*R*)-2,3-dipropylcyclobutan-1-one **s9.**⁹ The compound was prepared using the procedure developed by Nicolaou and co-workers.⁹ To a solution of 0.250 g of cyclobutante **s8** (0.87 mmol) in 10:1 acetone:water (0.1 M) were added 0.20 mL of 2,6-lutidine (1.74 mmol), 0.153 g of 4-methylmorpholine *N*-oxide (1.31 mmol) and 0.11 mL of osmium tetroxide (4% in H_2O , 0.02 mmol). The reaction progress was monitored using TLC. When the starting material had been consumed, 0.420 g of $\text{PhI}(\text{OAc})_2$ (1.31 mmol) was added. After stirring for 2 h, the reaction was quenched with saturated aqueous sodium thiosulfate (10 mL). The mixture was extracted with ethyl acetate (3×10 mL), washed with saturated aqueous copper sulfate (2×20 mL), dried over MgSO_4 , and concentrated *in vacuo*. The crude residue was purified by MPLC (49:1 hexanes:EtOAc) to give **s9** as a clear oil (0.097 g, 72%): $R_f = 0.78$ (10:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 3.28 – 3.22 (m, 1H), 3.14 – 3.08 (m, 1H), 2.51 – 2.39 (m, 2H), 1.61 – 1.54 (m, 1H), 1.46 – 1.19 (m, 7H), 0.94 (t, $J = 7.5$ Hz, 3H), 0.90 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 212.0 (C), 61.7 (CH), 50.2 (CH₂), 32.3 (CH₂), 27.4 (CH), 26.4 (CH₂), 21.4 (CH₂), 21.2 (CH₂), 14.1 (CH₃), 14.1 (CH₃); ATR-FTIR (thin film): 2957, 2928, 2873, 1775, 1465 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{10}\text{H}_{19}\text{O}$ [$\text{M} + \text{H}]^+$: 155.14398, found 155.14360.


F. General Procedure for Synthesis of *o*-Cyclobutanol Carbamates

o-Cyclobutanol carbamates were prepared following the protocol reported by Fensome and co-workers.¹⁰




To a cooled (0 °C) 3 M solution of commercially available *N*-Boc aniline (1.0 equiv) in dry Et_2O under an inert atmosphere of argon was dropwise added *t*-butyl lithium (1.9 M in pentane, 2.5 equiv) using a syringe pump. After 3 h, a solution of the cycloalkanone (1.5 equiv) in dry Et_2O was added dropwise. The resulting mixture was allowed to warm to rt. The reagents were quenched through the addition of a saturated aq soln of NH_4Cl . The resulting mixture was diluted with EtOAc. The two layers were separated, and the aqueous layer was extracted 3 additional times with EtOAc (3×5 mL). The combined organic extracts were washed with brine, dried over MgSO_4 and the filtrate concentrated under reduced pressure. The resulting residue was purified by MPLC to afford the product.

G. Characterization data for *o*-Cyclobutanol Carbamates




tert-Butyl (2-(1-hydroxycyclobutyl)-5-methoxyphenyl)carbamate **s1'f.** The general procedure was followed at –78 °C using 1.000 g of commercially available *tert*-butyl (2-bromo-5-methoxyphenyl) carbamate (3.31 mmol), 4.36 mL of *t*


butyl lithium (8.28 mmol) and 0.370 mL of cyclobutanone (4.97 mmol). Purification using MPLC (5:1 hexanes:EtOAc) gave the product as a white sticky solid (0.296 g, 24%): $R_f = 0.48$ (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.82 (br s, 1H), 7.60 (d, $J = 3.0$ Hz, 1H), 7.18 (d, $J = 8.5$ Hz, 1H), 6.53 (dd, $J = 8.5$ Hz, 3.0 Hz, 1H), 3.80 (s, 3H), 2.59 – 2.53 (m, 2H), 2.40 (s, 1H), 2.39 – 2.31 (m, 2H), 2.05 – 1.97 (m, 1H), 1.67 – 1.59 (m, 1H), 1.50 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.8 (C), 153.1 (C), 138.6 (C), 125.8 (CH), 124.9 (C), 108.3 (CH), 107.0 (CH), 80.2 (C), 77.1 (C), 55.4 (CH₃), 35.6 (CH₂), 28.4 (CH₃), 13.8 (CH₂); ATR-FTIR (thin film): 3346, 2978, 2360, 1727, 1703, 1616, 1528, 1239, 876 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{23}\text{NO}_4\text{Na}$ [M + Na]⁺: 316.1517, found 316.1515.



tert-Butyl (2-(1-hydroxyoxetane)phenylcarbamate s5a. The general procedure was followed by using 0.800 g of *N*-Boc aniline (4.14 mmol), 5.50 ml of *t*-butyl lithium (10.4 mmol) and 0.360 mL of commercially available 3-oxetanone (6.20 mmol). Purification by MPLC (5:1 hexanes:EtOAc) gave the product as a yellow solid (0.420 g, 38%): $R_f = 0.53$ (1:1 hexanes:EtOAc); mp = 102 – 104 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.54 (d, $J = 8.0$ Hz, 1H), 7.29 – 7.25 (m, 1H), 7.18 (s, 1H), 7.14 – 7.08 (m, 2H), 4.96 (d, $J = 7.0$ Hz, 2H), 4.74 (d, $J = 7.0$ Hz, 3H), 1.47 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.1 (C), 135.6 (C), 133.1 (C), 129.2 (CH), 126.1 (CH), 126.1 (CH), 124.7 (CH), 124.1 (CH), 82.8 (CH₂), 81.1 (C), 75.9 (C), 28.3 (CH₃); ATR-FTIR (thin film): 3360, 2978, 2875, 1698, 1587, 1514, 1450, 1367, 1236, 1155, 1052, 1025, 976, 729 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{19}\text{NO}_4\text{Na}$ [M + Na]⁺: 288.1213, found 288.1212.




tert-Butyl (2-(1-Hydroxy-3-*tert*-butylcyclobutyl)phenylcarbamate s5c. The general procedure was followed by using 0.300 g of *N*-Boc aniline (1.56 mmol), 2.0 mL of *t*-butyl lithium (5.18 mmol) and 0.290 g of 3-*tert*-butylcyclobutanone (2.39 mmol).¹¹ Purification by MPLC (15:1 hexanes:EtOAc) gave the product as a yellow sticky solid, as a 2:1 mixture of atropisomers (0.17 g, 33%): $R_f = 0.78$ (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 8.02 (s, 0.93H), 7.99 (d, $J = 8.0$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 0.41H), 7.53 (s, 0.42H), 7.37 (dd, $J = 8.0$ Hz, 1.5 Hz, 1H), 7.29 (dt, $J = 8.0$ Hz, 2.0 Hz, 1H), 7.24 (dd, $J = 8.0$ Hz, 2.0 Hz, 0.39 H), 7.18 (dd, $J = 7.5$ Hz, 1.5 Hz, 0.44H), 7.04 – 7.00 (m, 1.43H), 2.56 – 2.47 (m, 2H), 2.26 (d, $J = 9.0$ Hz, 2H), 2.11 – 2.02 (m, 2H), 1.64 – 1.57 (m, 1H), 1.51 (s, 13.6H), 0.84 (s, 9H), 0.81 (s, 4.51H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.5 (C), 153.2 (C), 138.0 (C), 136.6 (C), 135.0 (C), 131.8 (C), 128.6 (CH), 128.4 (CH), 125.3 (CH), 124.8 (CH), 123.1 (CH), 122.4 (CH), 122.3 (CH), 121.9 (CH), 80.3 (C), 80.1 (C), 74.1 (C), 71.8 (C), 40.4 (CH), 36.8 (CH₂), 35.5 (CH₂), 30.9 (C), 30.8 (C), 28.4 (CH₃), 26.6 (CH₃), 26.3 (CH₃) (only visible peaks); ATR-FTIR (thin film): 3356, 2956, 2866, 1729, 1704, 1587, 1520, 1450, 1366, 1304, 1236, 1161, 1025, 755 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{29}\text{NO}_3\text{Na}$ [M + Na]⁺: 342.2040, found 342.2045.




tert-Butyl (2-(1-Hydroxy-3-phenylcyclobutyl)phenylcarbamate s5d. The general procedure was followed by using 0.300 g of *N*-Boc aniline (1.56 mmol), 2.30 mL of *t*-butyl lithium (3.89 mmol) and 0.338 g of 3-phenylcyclobutanone (2.33 mmol).¹¹ Purification by MPLC (15:1 hexanes:EtOAc) gave the product as a white sticky solid, as a 3:1 mixture of atropisomers (0.15 g, 28%): $R_f = 0.68$ (5:1 hexanes:EtOAc); mp = 153 – 155 °C. ^1H NMR (500 MHz, CDCl_3) δ 8.01 (s,


1.30H), 7.99 (s, 0.45H), 7.76 (d, J = 8.5 Hz, 0.38H), 0.33 (s, 0.43H), 7.49 (dd, J = 8.5 Hz, 1.5 Hz, 1.01H), 7.35 – 7.27 (m, 5.81H), 7.24 – 7.18 (m, 2.57H), 7.12 – 7.06 (m, 1.36H), 3.97 (quin, J = 8.5 H, 0.40 H), 3.13 – 3.07 (m, 1.82H), 3.04 – 2.97 (m, 1.31H), 2.88 – 2.81 (m, 1.66H), 2.69 – 2.63 (m, 0.86H), 2.57 – 2.51 (m, 1.82H), 1.53 (s, 3.24H), 1.52 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.7 (C), 153.3 (C), 144.7 (C), 144.1 (C), 137.9 (C), 136.3 (C), 135.4 (C), 131.6 (C), 128.9 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 126.7 (CH), 126.5 (CH), 126.3 (CH), 126.2 (CH), 125.6 (CH), 124.8 (CH), 123.6 (CH), 122.8 (CH), 122.7 (CH), 122.4 (CH), 80.5 (C), 80.3 (C), 75.0 (C), 72.7 (C), 43.2 (CH₂), 42.2 (CH₂), 34.2 (CH), 30.7 (CH₃), 28.4 (CH₃) only visible peaks; ATR-FTIR (thin film): 3362, 2977, 2930, 1726, 1703, 1586, 1519, 1450, 1367, 1246, 1155, 1048, 1025, 750, 698 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_3\text{Na} [\text{M} + \text{Na}]^+$: 362.1726, found 362.1732.




tert-Butyl (2-(1-hydroxycyclobutyl)phenyl)carbamate s5e. The general procedure was followed by using 0.495 g of *N*-Boc aniline (2.56 mmol), 3.40 mL of *t*-butyl lithium (6.40 mmol) and 0.560 g of 2-phenylcyclobutanone (3.84 mmol).¹² Purification by MPLC (15:1 hexanes:EtOAc) gave the product as a white sticky solid (0.370 g, 43%): R_f = 0.78 (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 8.00 (d, J = 8.0 Hz, 1H), 7.93 (s, 1H), 7.47 – 7.45 (m, 3H), 7.40 (t, J = 8.0 Hz, 2H), 7.31 – 7.27 (m, 2H), 7.05 (dt, J = 7.5 Hz, 1.0 Hz, 1H), 4.20 (m, 1H), 2.56 – 2.45 (m, 3H), 2.29 – 2.22 (m, 1H), 2.07 (d, J = 1.0 Hz, 1H), 1.52 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.1 (C), 138.4 (C), 137.5 (C), 133.3 (C), 128.8 (CH), 128.8 (CH), 128.5 (CH), 127.2 (CH), 125.2 (CH), 122.5 (CH), 121.8 (CH), 80.2 (C), 80.0 (C), 47.8 (CH), 33.6 (CH₂), 28.4 (CH₃), 21.7 (CH₂); ATR-FTIR (thin film): 3374, 2977, 2360, 2341, 1726, 1585, 1522, 1449, 1392, 1305, 1239, 1161, 1048, 753 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_3\text{Na} [\text{M} + \text{Na}]^+$: 362.1722, found 362.1732.




tert-Butyl (2-(1-hydroxycyclobutyl)(2-bromophenyl)carbamate s5f. The general procedure was followed by using 0.200 g of *N*-Boc aniline (1.04 mmol), 1.40 mL of *t*-butyl lithium (2.60 mmol) and 0.356 g of 2-(2-bromophenyl)cyclobutanone (1.56 mmol).¹³ Purification by MPLC (12:1 hexanes:EtOAc) gave the product as a brown solid (0.200 g, 46%): R_f = 0.53 (5:1 hexanes:EtOAc); mp = 196 – 198 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.96 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.67 (s, 1H), 7.60 (t, J = 8.0 Hz, 2H), 7.39 (t, J = 7.5 Hz, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.15 (t, J = 7.5 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 4.56 (t, J = 7.5 Hz, 1H), 2.60 – 2.53 (m, 1H), 2.48 – 2.39 (m, 2H), 2.29 – 2.23 (m, 2H), 1.45 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.1 (C), 138.5 (C), 137.3 (C), 133.1 (CH), 132.8 (C), 130.4 (CH), 128.7 (CH), 128.5 (CH), 127.5 (CH), 125.9 (C), 125.7 (CH), 122.6 (CH), 121.7 (CH), 80.8 (C), 80.0 (C), 46.9 (CH), 33.7 (CH₂), 28.3 (CH₃), 22.6 (CH₂); ATR-FTIR (thin film): 3368, 2977, 1704, 1586, 1521, 1448, 1241, 1157, 1048, 1023, 752, 736 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{24}\text{NO}_3\text{NaBr} [\text{M} + \text{Na}]^+$: 440.0829, found 440.0837.



tert-Butyl (2-(1-hydroxycyclobutyl)phenylcarbamate s5g. The general procedure was followed by using 0.250 g of *N*-Boc aniline (1.30 mmol), 1.50 mL of *t*-butyl lithium (3.30 mmol) and 0.210 mL of commercially available bicyclo[3.2.0]hept-2-en-6 one (1.95 mmol). Purification by MPLC (12:1 hexanes:EtOAc) gave the product, a brown sticky solid, as a mixture of diastereomers (0.17 g, 43%): R_f = 0.58 (7:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 8.93 (s, 0.10H), 8.27 (d, J = 8.0 Hz, 0.11H), 7.85 (d, J = 8.0 Hz, 0.86H), 7.49 – 7.48 (m, 0.83H), 7.47 – 7.45 (m, 0.22H), 7.38 – 7.34 (m, 0.27H), 7.32 – 7.25 (m, 2.23H), 7.06 – 7.02 (m, 1H), 7.00 (dd, J = 8.0 Hz, 1.5 Hz, 0.10H), 5.99 – 5.95 (m, 1.93H), 5.89 (s, 0.22H), 3.45 – 3.42 (m, 1H), 3.16 – 3.08 (m, 2H), 2.90 (d, J = 8.0 Hz, 1H), 2.66 – 2.60 (m, 1H), 2.48 (s, 1H), 2.14 – 2.11 (m, 1H), 1.51 (s, 9H), 1.50 (s, 1.55H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.1 (C), 150.9 (C), 139.2 (C), 136.9 (C), 135.6 (CH), 134.4 (CH), 132.7 (CH), 132.4 (CH), 131.9 (CH), 128.4 (CH), 125.3 (CH), 122.9 (CH), 122.7 (CH), 121.0 (CH), 120.4 (CH), 117.1 (CH), 115.8 (CH), 80.5 (C), 80.0 (C), 77.4 (C), 45.7 (CH), 41.9 (CH_2), 39.8 (CH), 33.4 (CH_2), 28.4 (CH_3), 28.3 (CH_3) only visible peaks; ATR-FTIR (thin film): 3371, 2977, 2928, 1727, 1704, 1585, 1515, 1448, 1238, 1153, 1048, 1024, 748, 726 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{23}\text{NO}_3\text{Na}$ [$\text{M} + \text{Na}$] $^+$: 324.1571, found 324.1576.




Spiro(2-(1-hydroxycyclobutyl)phenylbenzoxazine s5'h. The general procedure was followed by using 0.200 g of *N*-Boc aniline (1.04 mmol), 1.32 mL of *t*-butyl lithium (2.50 mmol) and 0.170 g of bicyclo[3.2.0]heptan-6-one (1.50 mmol).¹⁴ Purification by MPLC (5:1 hexanes:EtOAc) gave the product as a orange solid (0.07 g, 30%): R_f = 0.30 (3:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 9.19 (s, 1H), 7.36 (d, *J* = 7.5 Hz, 1H), 7.22 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.10 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 6.87 (d, *J* = 7.5 Hz, 1H), 2.90 – 2.86 (m, 1H), 2.77 – 2.72 (m, 1H), 2.65 (quin, *J* = 7.0 Hz, 1H), 2.21 – 2.06 (m, 3H), 1.91 – 1.86 (m, 1H), 1.70 (dd, *J* = 11.5 Hz, 6.0 Hz, 1H), 1.59 – 1.46 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.0 (C), 133.9 (C), 128.5 (CH), 126.4 (C), 123.6 (CH), 122.6 (CH), 114.3 (CH), 80.5 (C), 52.6 (CH), 37.9 (CH₂), 32.6 (CH₂), 31.4 (CH), 26.9 (CH₂), 25.6 (CH₂); ATR-FTIR (thin film): 3245, 2950, 1708, 1597, 1501, 1353, 1250, 1157, 1073, 1019, 751 cm⁻¹. HRMS (ESI) m/z calcd for C₁₄H₁₆NO₂ [M + H]⁺: 230.1176, found 230.1181.



N-(2-(1-Hydroxycyclobutyl)phenyl)carbamate s5i. The general procedure was followed by using 0.200 g of *N*-Boc aniline (1.04 mmol), 1.32 mL of *t*-butyl lithium (2.50 mmol) and 0.237 g of bicyclo[6.2.0]decan-9-one (1.50 mmol). Purification by MPLC (15:1 hexanes:EtOAc) gave the product as a white sticky solid (0.12 g, 33%): R_f = 0.54 (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.89 (d, J = 8.0 Hz, 1H), 7.79 (br s, 1H), 7.35 – 7.33 (m, 1H), 7.30 – 7.26 (m, 1H), 7.05 – 7.01 (m, 1H), 2.88 – 2.83 (m, 1H), 2.57 – 2.52 (m, 1H), 2.14 (br s, 1H), 1.99 – 1.83 (m, 4H), 1.82 – 1.71 (m, 2H), 1.59 – 1.42 (m, 13H), 1.32 – 1.17 (m, 4H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.1 (C), 137.6 (C), 134.0 (C), 128.3 (CH), 124.4 (CH), 122.6 (CH), 122.4 (CH), 79.9 (C), 75.2 (C), 49.2 (CH), 40.2 (CH_2), 31.5 (CH), 30.2 (CH_2), 29.2 (CH₂), 28.6 (CH₂), 28.4 (CH₃), 25.8 (CH₂), 25.2 (CH₂), 22.6 (CH₂); ATR-FTIR (thin film): 3365, 2975, 2919, 2850, 1729, 1704,

1586, 1519, 1449, 1367, 1245, 1160, 1048, 747 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{31}\text{NO}_3\text{Na} [\text{M} + \text{Na}]^+$: 368.2192, found 368.2202.




N-(2-(1-Hydroxycyclobutyl)phenyl)carbamate s5j. The general procedure was followed by using 0.200 g of *N*-Boc aniline (1.04 mmol), 1.32 mL of *t*-butyl lithium (2.50 mmol) and 0.240 g of (2*S*,3*S*)-2,3-dipropylcyclobutan-1-one (1.50 mmol). Purification by MPLC (15:1 hexanes:EtOAc) gave the product as a white sticky solid (0.14 g, 40%): R_f = 0.78 (10:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 7.93 (s, 1H), 7.31 (dd, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.28 – 7.24 (m, 1H), 7.00 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 2.72 – 2.64 (m, 2H), 2.25 (br s, 1H), 2.03 – 1.93 (m, 2H), 1.71 – 1.54 (m, 2H), 1.51 (s, 9H), 1.48 – 1.40 (m, 4H), 1.34 – 1.25 (m, 1H), 1.22 – 1.12 (m, 1H), 1.00 (t, *J* = 7.0 Hz, 3H), 0.91 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 153.1 (C), 137.6 (C), 133.6 (C), 128.3 (CH), 124.7 (CH), 122.4 (CH), 121.9 (CH), 79.9 (C), 75.9 (C), 46.2 (CH), 39.4 (CH₂), 32.6 (CH₂), 30.4 (CH), 28.4 (CH₃), 27.4 (CH₂), 23.4 (CH₂), 20.8 (CH₂), 14.8 (CH₃), 14.3 (CH₃); ATR-FTIR (thin film): 3365, 2975, 2919, 2850, 1729, 1704, 1586, 1519, 1449, 1367, 1245, 1160, 1048, 747 cm⁻¹. HRMS (EI) m/z calcd for C₂₁H₃₃NO₃: 347.24507, found 347.24605.

II. Synthesis of *o*-Cyclobutanol Aryl Azides


A. General Procedure

The *o*-cyclobutanol aryl azides were prepared following the protocol reported by Moses and co-workers.¹⁵




To a cooled solution (0 °C) of o-cyclobutanol aniline **s3** in MeCN (0.2 M), was added dropwise *t*-BuONO (4.0 equiv), Me₃SiN₃ (3.0 equiv). The resulting solution was warmed to room temperature. After 1.5 h, the reaction mixture was concentrated in vacuo. The residue was purified by MPLC (10:1 – 7:1 hexanes:EtOAc) to afford the *ortho*-cyclobutanol aryl azide.


B. Characterization Data for *o*-Cyclobutanol Azides




***o*-Cyclobutanol aryl azide 8a.** The general procedure was followed by using 0.155 g of aniline **s3a** (0.950 mmol), 0.450 mL of *t*-BuONO (3.80 mmol), 0.37 mL Me₃SiN₃ (2.85 mmol) in 4.8 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.150 g, 82%): R_f = 0.52 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.34 (dd, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.31 (dd, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.17 (dd, *J* = 8.0 Hz, 1.0 Hz, 1H), 7.12 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 3.24 (s, 1H), 2.58 – 2.52 (m, 2H), 2.40 – 2.34 (m, 2H), 2.15 – 2.08 (m, 1H), 1.70 – 1.64 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 137.4 (C), 136.2 (C), 128.8 (CH), 126.4 (CH), 124.7 (CH), 118.8 (CH), 76.8 (C), 35.2 (CH₂), 14.5 (CH₂); ATR-FTIR (thin film): 3397, 2946, 2125, 2087, 1486, 1444, 1293, 1131, 751 cm⁻¹. HRMS (ESI) m/z calcd for C₁₀H₁₂NO [M + H – N₂]⁺: 162.0923, found 162.0919.




***o*-Cyclobutanol aryl azide 8b.** The general procedure was followed by using 0.152 g of aniline **s3b** (0.790 mmol), 0.380 mL of *t*-BuONO (3.16 mmol), 0.310 mL of Me₃SiN₃ (2.37 mmol) in 3.9 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.160 g, 94%): R_f = 0.40 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.10 (d, *J* = 8.5 Hz, 1H), 6.91 (d, *J* = 1.0 Hz, 1H), 6.84 (dd, *J* = 8.5 Hz, 1.0 Hz, 1H), 3.81 (s, 3H), 3.16 (br s, 1H), 2.55 – 2.50 (m, 2H), 2.39 – 2.34 (m, 2H), 2.14 – 2.07 (m, 1H), 1.72 – 1.64 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 156.8 (C), 137.6 (C), 129.6 (C), 119.8 (CH), 113.1 (CH), 113.0 (CH), 76.7 (C), 55.7 (CH₃), 35.2 (CH₂), 14.3 (CH₂); ATR-FTIR (thin film): 3513, 2941, 2836, 2108, 1579, 1485, 1312, 1237, 1038, 803 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₃N₃O₂Na [M + Na]⁺: 242.0899, found 242.0905.



***o*-Cyclobutanol aryl azide 8c.** The general procedure was followed by using 0.150 g of aniline **s3c** (0.84 mmol), 0.40 mL of *t*-BuONO (3.16 mmol), 0.33 mL of Me₃SiN₃ (2.37 mmol) in 3.5 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.122 g, 72%): R_f = 0.55 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.14 (s, 1H), 7.12 (s, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 3.09 (s, 1H), 2.57 – 2.52 (m, 2H), 2.39 – 2.36 (m, 2H), 2.35 (s, 3H), 2.15 – 2.08 (m, 1H), 1.72 – 1.64 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 135.9 (C), 134.5 (C), 134.4 (C), 129.2 (CH), 127.1 (CH), 118.7 (CH), 76.8 (C), 35.2 (CH₂), 21.0 (CH₃), 14.5 (CH₂); ATR-FTIR (thin film): 3417, 2947, 2114, 1492, 1300, 1157, 1137, 910, 807 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₄NO [M + H – N₂]⁺: 176.1077, found 176.1075.



***o*-Cyclobutanol aryl azide 8d.** The general procedure was followed by using 0.232 g of aniline **s3d** (1.00 mmol), 0.480 mL of *t*-BuONO (3.16 mmol), 0.400 mL of Me₃SiN₃ (2.37 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.210 g, 80%): R_f = 0.55 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.58 (d, *J* = 7.5 Hz, 2H), 7.26 (d, *J* = 8.0 Hz, 1H), 3.06 (s, 1H), 2.59 – 2.54 (m, 2H), 2.42 – 2.37 (m, 2H), 2.21 – 2.12 (m, 1H), 1.76 – 1.68 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 141.1 (C), 136.8 (C), 126.8 (q, *J*_{CF} = 32.5 Hz, C), 125.8 (q, *J*_{CF} = 3.8 Hz, CH), 123.9 (q, *J*_{CF} = 269.9 Hz, C), 123.6 (q, *J*_{CF} = 3.9 Hz, CH), 119.0 (CH), 76.5 (C), 35.0 (CH₂), 14.5 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ –62.3; ATR-FTIR (thin film): 3383, 2952, 2109, 1614, 1496, 1293, 1272, 1119, 1081, 903, 822 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₁NOF₃ [M + H – N₂]⁺: 230.0790, found 230.0792.




***o*-Cyclobutanol aryl azide 8e.** The general procedure was followed by using 0.114 g of aniline **s3e** (0.460 mmol), 0.220 mL of *t*-BuONO (1.84 mmol), 0.180 mL of Me₃SiN₃ (1.38 mmol) in 2.31 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.090 g, 70%): R_f = 0.54 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz,

CDCl_3) δ 7.19 – 7.16 (m, 3H), 3.14 (s, 1H), 2.55 – 2.49 (m, 2H), 2.40 – 2.35 (m, 2H), 2.17 – 2.09 (m, 1H), 1.74 – 1.65 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 145.8 (C), 138.1 (C), 136.1 (C), 121.2 (CH), 120.5 (q, $J_{CF} = 255.4$ Hz, C), 119.8 (CH), 119.7 (CH), 76.4 (C), 35.1 (CH_2), 14.3 (CH_2); ^{19}F NMR (282 MHz, CDCl_3) δ –58.5; ATR-FTIR (thin film): 3390, 2953, 2118, 1483, 1249, 1208, 1158, 890, 817 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{11}\text{NO}_2\text{F}_3$ [$\text{M} + \text{H} - \text{N}_2$] $^+$: 246.0742, found 246.0742.




N-(2-(1-Hydroxy-3-*tert*-butylcyclobutyl)phenyl)aniline **s3f.** *o*-Cyclobutanol carbamate **s3f** (0.500 g, 1.34 mmol) was dissolved in 1 mL of dioxane. To the stirred solution was added dropwise 4 mL of a 4 M solution of HCl in dioxane. The reaction progress was monitored by TLC. When the starting material was consumed, the mixture was neutralized by adding a saturated solution of NaHCO_3 (until effervescence stopped). The solution was extracted 3×10 mL of EtOAc. The organic layer was dried over Na_2SO_4 , filtered, and the filtrate was concentrated *in vacuo* to afford **s3f** as a yellow solid, which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide **8f**.** The general procedure was followed by using 0.280 g of aniline **s3f** (1.03 mmol), 0.490 mL of *t*-BuONO (4.12 mmol), 0.410 mL of Me_3SiN_3 (3.09 mmol) in 5.2 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.243 g, 79%): $R_f = 0.52$ (3:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.26 (d, $J = 8.5$ Hz, 1H), 6.72 (d, $J = 2.5$ Hz, 1H), 6.66 (dd, $J = 8.5$ Hz, 2.5 Hz, 1H), 3.83 (s, 3H), 2.96 (s, 1H), 2.55 – 2.50 (m, 2H), 2.38 – 2.33 (m, 2H), 2.13 – 2.04 (m, 1H), 1.69 – 1.63 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.9 (C), 138.5 (C), 128.9 (C), 127.3 (CH), 109.4 (CH), 105.2 (CH), 76.4 (C), 55.5 (CH_3), 35.4 (CH_2), 14.4 (CH_2); ATR-FTIR (thin film): 3400, 2915, 2110, 2107, 1608, 1502, 1315, 1229, 1123, 830 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$: 242.0898, found 242.0904.




***o*-Cyclobutanol aryl azide **8g**.** The general procedure was followed by using 0.178 g of aniline **s3g** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me_3SiN_3 (3.03 mmol) in 5.00 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a brown oil (0.170 g, 80%): $R_f = 0.55$ (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.24 (d, $J = 7.5$ Hz, 1H), 6.99 (s, 1H), 6.95 – 6.93 (m, 1H), 3.06 (s, 1H), 2.39 – 2.34 (m, 5H), 2.13 – 2.05 (m, 1H), 1.70 – 1.62 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 138.9 (C), 137.1 (C), 133.4 (C), 126.2 (CH), 125.5 (CH), 119.4 (CH), 76.6 (C), 35.3 (CH_2), 21.1 (CH_3), 14.4 (CH_2); ATR-FTIR (thin film): 3417, 2947, 2114, 1492, 1300, 1157, 1137, 910, 807 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{14}\text{NO}$ [$\text{M} + \text{H} - \text{N}_2$] $^+$: 176.1074, found 176.1075.




***o*-Cyclobutanol aryl azide **8h**.** The general procedure was followed by using 0.183 g of aniline **s3h** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me_3SiN_3 (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a yellow oil (0.180 g, 85%): $R_f = 0.53$ (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.28 (dd, $J = 8.5$ Hz, 6.5 Hz, 1H), 6.88 (dd, $J = 9.0$ Hz, 2.0 Hz, 1H), 6.81 (dt, $J = 8.5$ Hz, 2.5 Hz, 1H), 3.03 (s, 1H), 2.54 – 2.48 (m, 2H), 2.38 – 2.33 (m, 2H), 2.15 – 2.07 (m, 1H), 1.70 – 1.62 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ


162.5 (d, $J_{CF} = 247.6$ Hz, C), 139.1 (d, $J_{CF} = 9.1$ Hz, C), 132.3 (d, $J_{CF} = 3.3$ Hz, C), 127.8 (d, $J_{CF} = 9.0$ Hz, CH), 111.3 (d, $J_{CF} = 20.3$ Hz, CH), 106.3 (d, $J_{CF} = 24.1$ Hz, CH), 76.4 (C), 35.3 (CH₂), 14.5 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -112.9; ATR-FTIR (thin film): 3394, 2950, 2109, 1593, 1498, 1412, 1292, 1230, 1140, 959, 842, 666 cm⁻¹. HRMS (CI) m/z calcd for C₁₀H₁₁N₃OF [M + H]⁺: 208.0884, found 208.0886.



***o*-Cyclobutanol aryl azide 8i.** The general procedure was followed by using 0.233 g of aniline s3i (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a yellow oil (0.210 g, 80%): R_f = 0.55 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.45 (d, $J = 8.5$ Hz, 1H), 7.38 (d, $J = 3.5$ Hz, 2H), 3.2 (s, 1H), 2.58 – 2.52 (m, 2H), 2.42 – 2.36 (m, 2H), 2.19 – 2.10 (m, 1H), 1.74 – 1.65 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 139.7 (C), 138.5 (C), 131.2 (q, $J_{CF} = 33.1$ Hz, C), 127.0 (CH), 123.5 (q, $J_{CF} = 270.3$ Hz, C), 121.5 (q, $J_{CF} = 3.9$ Hz, CH), 115.6 (q, $J_{CF} = 3.9$ Hz, CH), 76.5 (C), 35.1 (CH₂), 14.4 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -63.2; ATR-FTIR (thin film): 3490, 2924, 2107, 1417, 1328, 1274, 1123, 1086, 902, 871, 834, 656 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₁NOF₃ [M + H - N₂]⁺: 230.0791, found 230.0793.




***o*-Cyclobutanol aryl azide 8j.** The general procedure was followed by using 0.197 g of aniline s3j (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a yellow oil (0.190 g, 85%) as a mixture of rotamers: R_f = 0.56 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.12 (d, $J = 8.5$ Hz, 1H), 7.1 (t, $J = 8.0$ Hz, 0.19H), 6.84 (d, $J = 9.5$ Hz, 1H), 6.84 (s, 0.11H), 2.97 (s, 1H), 2.69 – 2.65 (m, 0.39H), 2.54 – 2.48 (m, 2H), 2.47 – 2.43 (m, 0.38H), 2.38 – 2.32 (m, 2H), 2.24 (d, $J = 1.5$ Hz, 3H), 2.21 (d, $J = 2.5$ Hz, 0.56H), 2.15 – 2.08 (m, 1H), 1.88 – 1.81 (m, 0.20H), 1.71 – 1.63 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 160.6 (d, $J_{CF} = 244.1$ Hz, C), 159.6 (d, $J_{CF} = 246.1$ Hz, C), 136.2 (d, $J_{CF} = 7.3$ Hz, C), 131.9 (d, $J_{CF} = 2.9$ Hz, C), 130.4 (d, $J_{CF} = 5.9$ Hz, CH), 129.3 (d, $J_{CF} = 5.6$ Hz, CH), 120.9 (d, $J_{CF} = 18.1$ Hz, C), 113.9 (d, $J_{CF} = 3.5$ Hz, CH), 106.0 (d, $J_{CF} = 25.8$ Hz, CH), 76.4 (C), 37.3 (d, $J_{CF} = 4.1$ Hz, CH₂), 35.4 (CH₂), 29.7 (C), 17.6 (CH₂), 14.5 (CH₂), 14.4 (d, $J_{CF} = 5.4$ Hz, CH₂), 14.1 (d, $J_{CF} = 3.6$ Hz, CH₃), only visible signals; ¹⁹F NMR (282 MHz, CDCl₃) δ -117.4, -116.7 ; ATR-FTIR (thin film): 3353, 2949, 2106, 1588, 1504, 1313, 1239, 1164, 1134, 1091, 889, 839 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₃NOF [M + H - N₂]⁺: 194.0980, found 194.0981.



***o*-Cyclobutanol aryl azide 8k.** The general procedure was followed by using 0.195 g of aniline s3k (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a orange oil (0.180 g, 80%): R_f = 0.53 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.10 – 7.06 (m, 1H), 6.94 (dd, $J = 8.0$ Hz, 1.5 Hz, 1H), 6.84 (dd, $J = 8.0$ Hz, 1.0 Hz, 1H), 3.90 (s, 3H), 3.31 (s, 1H), 2.57 – 2.51 (m, 2H), 2.41 – 2.35 (m, 2H), 2.15 – 2.07 (m, 1H), 1.71 – 1.64 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 154.5 (C), 138.1 (C), 125.3 (C), 125.2 (CH), 118.1 (CH), 111.3 (CH), 77.1 (C), 56.1 (CH₃), 35.4 (CH₂), 14.5 (CH₂); ATR-


FTIR (thin film): 3543, 2941, 2146, 2118, 2096, 1579, 1455, 1439, 1310, 1261, 1033, 734 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₃N₃O₂Na [M + Na]⁺: 242.0899, found 242.0905.



***o*-Cyclopropanol aryl azide 10a.** The general procedure was followed by using 0.0400 g of aniline **3I** (0.270 mmol),¹⁶ 0.130 mL of *t*-BuONO (1.08 mmol), 0.110 mL of Me₃SiN₃ (0.810 mmol) in 2.0 mL of MeCN. Purification by MPLC (5:1 hexanes:EtOAc) gave the product as a yellow oil (0.03 g, 65%): R_f = 0.56 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.35 – 7.30 (m, 2H), 7.20 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.11 – 7.07 (m, 1H), 3.18 (s, 1H), 1.16 – 1.13 (m, 2H), 0.94 – 0.91 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 139.5 (C), 133.2 (C), 129.1 (CH), 128.8 (CH), 124.8 (CH), 118.3 (CH), 55.2 (C), 13.9 (CH₂); ATR-FTIR (thin film): 3391, 2926, 2853, 2360, 2127, 2093, 1491, 1445, 1293, 1225, 753 cm⁻¹. HRMS (ESI) m/z calcd for C₉H₉N₃ONa [M + Na]⁺: 198.0644, found 198.0646.


C. General Procedure for Synthesis of *o*-Cyclobutanol Azides from *o*-Cyclobutanol Carbamates

Deprotection of the *N*-Boc carbamate was accomplished following two different strategies reported by Hruby and co-workers and Harigaya and co-workers.¹⁷




Method A.^{17a} The original procedure described by Hruby and co-workers was slightly modified. The *o*-cyclobutanol carbamate was dissolved in 1 mL of dioxane. To the stirred solution was added dropwise a 4 M solution of HCl in dioxane. The reaction progress was monitored by TLC. When the starting material was consumed, the mixture was neutralized by adding a saturated solution of NaHCO₃ (until effervescence stopped). The solution was extracted 3 × 10 mL of EtOAc. The organic layer was dried over Na₂SO₄, filtered, and the filtrate was concentrated *in vacuo*. The resulting aniline was submitted to the next step without further characterization or purification.

Method B.^{17b} The original procedure developed by Harigaya and co-workers was slightly modified. The *o*-cyclobutanol carbamate was dissolved in a 3:1 v:v solution of MeOH and H₂O (1 mL / mmol). To the resulting solution was added K₂CO₃ (3.0 equiv), and the mixture was heated to reflux. The reaction progress was monitored using TLC. Once starting material was consumed, the reaction mixture was cooled to room temperature and was concentrated *in vacuo*. The resulting mixture was diluted with EtOAc. The organic layer was separated, dried over Na₂SO₄, filtered and the filtrate was concentrated *in vacuo* and submitted to the next step without further characterization or purification.




N-(2-(1-Hydroxyoxetane)phenyl)aniline s3m. Method B was followed using 0.460 g of **s5b** (1.74 mmol), 0.721 g of K_2CO_3 (5.22 mmol) to give **s3m** as a yellow solid (0.167 g, 58%) which was submitted to the next step without further characterization or purification.

***o*-Oxetane aryl azide 10b.** The general procedure was followed by using 0.167 g of aniline **s3m** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (5:1 hexanes:EtOAc) gave the product as a yellow oil (0.120 g, 62%): R_f = 0.47 (1:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.37 (dt, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.22 (dd, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.18 – 7.14 (m, 2H), 5.05 (d, *J* = 7.5 Hz, 2H), 4.81 (d, *J* = 7.5 Hz, 2H), 3.62 (s, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 137.4 (C), 132.4 (C), 129.9 (CH), 127.0 (CH), 125.1 (CH), 118.7 (CH), 82.8 (CH₂), 75.7 (C); ATR-FTIR (thin film): 3352, 2947, 2875, 2121, 2089, 1489, 1287, 972 cm⁻¹. HRMS (ESI) m/z calcd for C₉H₉N₃O₂Na [M + Na]⁺: 214.0593, found 214.0595.




N-(2-(1-Hydroxy-3-*tert*-butylcyclobutyl)phenyl)aniline s3n. Method A was followed using 0.500 g of **s5c** (1.56 mmol), 4 mL of HCl (4 M in dioxane) to give **s3n** as a yellow solid (0.220 g, 64%) which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide 10c.** The general procedure was followed by using 0.220 g of aniline **s3n** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product, a yellow oil, as a mixture of atropisomers (0.160 g, 63%): R_f = 0.57 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.48 (dd, *J* = 7.5 Hz, 1.5 Hz, 0.76H), 7.36 (dt, *J* = 7.5 Hz, 1.5 Hz, 0.78H), 7.31 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.26 – 7.21 (m, 1.88H), 7.18 – 7.15 (m, 1.75H), 7.12 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 3.45 (s, 0.70H), 2.76 (s, 0.88H), 2.64 – 2.57 (m, 0.94H), 2.52 – 2.47 (m, 1.56H), 2.32 – 2.27 (m, 2H), 2.22 – 2.17 (m, 2H), 2.16 – 2.10 (m, 1.64H), 1.63 – 1.55 (m, 0.88H), 0.85 (s, 7.05H), 0.82 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 137.9 (C), 137.1 (C), 137.0 (C), 135.7 (C), 128.8 (CH), 128.7 (CH), 126.5 (CH), 126.2 (CH), 124.8 (CH), 124.7 (CH), 119.0 (CH), 118.6 (CH), 73.0 (C), 70.8 (C), 40.7 (CH), 36.8 (CH), 36.5 (CH₂), 35.9 (CH₂), 30.9 (C), 30.9 (CH), 26.6 (CH₃), 26.3 (CH₃); ATR-FTIR (thin film): 3393, 2953, 2865, 2125, 2088, 1486, 1293, 1235, 750 cm⁻¹. HRMS (ESI) m/z calcd for C₁₄H₂₀NO [M + H – N₂]⁺: 218.1540, found 218.1545.




N-(2-(1-Hydroxy-3-phenylcyclobutyl)phenyl)aniline s3o. Method A was followed using 0.500 g of **s5d** (1.47 mmol), 4 mL of HCl (4 M in dioxane) to give **s3o** as a yellow solid (0.230 g, 68%) which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide 10d.** The general procedure was followed by using 0.230 g of aniline **s3o** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product, a yellow oil, as a mixture of atropisomers (0.220 g, 86%): R_f = 0.30 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, *J* = 8.0 Hz, 0.58H), 7.42 (t, *J* = 7.5 Hz, 0.60H), 7.36 – 7.27 (m, 6.77H), 7.26 – 7.19 (m, 4.84H), 7.15 (t, *J* = 7.5 Hz, 1H), 4.00 (quin, *J* = 9.0 Hz, 0.93H), 3.61 (s, 0.54H), 3.11 – 3.04 (m, 1.71H), 3.00 (s, 1H), 2.92 – 2.87 (m, 1.94H), 2.66 – 2.57 (m, 3.15H); ¹³C NMR (125 MHz, CDCl₃) δ 145.1 (C), 144.5 (C), 138.0 (C), 137.2 (C), 136.6 (C), 135.1 (C), 129.1 (CH), 129.0 (CH), 128.4 (CH), 128.4 (CH), 126.8 (CH), 126.6 (CH), 126.5 (CH), 126.3 (CH), 126.2 (CH), 126.0 (CH), 124.9 (CH), 124.9 (CH), 119.1 (CH), 118.7 (CH), 74.1 (C), 71.9 (C), 43.1 (CH₂), 42.4 (CH₂), 34.4 (CH), 30.8 (CH); ATR-FTIR (thin film): 3393, 3025, 2981, 2933, 2122, 2092, 1579, 1486, 1445, 1279, 747, 697 cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₁₆NO [M + H – N₂]⁺: 238.1229, found 238.1232.




N-(2-(1-Hydroxy-2-phenylcyclobutyl)phenyl)aniline s3p. Method A was followed using 0.500 g of **s5e** (1.47 mmol), 4 mL of HCl (4 M in dioxane) to give **s3p** as a yellow solid (0.242 g, 72%) which was submitted to the next step without further characterization or purification.

o-Cyclobutanol aryl azide 10e. The general procedure was followed by using 0.242 g of aniline **s3p** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a yellow oil, (0.180 g, 71%): R_f = 0.61 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.48 (dd, *J* = 8.0 Hz, 2.0 Hz, 1H), 7.41 – 7.36 (m, 4H), 7.34 – 7.31 (m, 1H), 7.29 – 7.25 (m, 1H), 7.17 – 7.13 (m, 2H), 3.95 (t, *J* = 9.0 Hz, 1H), 2.80 (d, *J* = 1.0 Hz, 1H), 2.72 – 2.66 (m, 1H), 2.62 – 2.54 (m, 1H), 2.38 – 2.33 (m, 1H), 2.29 – 2.23 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 139.4 (C), 137.1 (C), 136.8 (C), 128.9 (CH), 128.7 (CH), 128.3 (CH), 126.8 (CH), 126.8 (CH), 124.8 (CH), 119.0 (CH), 79.6 (C), 49.5 (CH), 32.3 (CH₂), 22.5 (CH₂); ATR-FTIR (thin film): 3542, 2948, 2123, 2089, 1577, 1484, 1444, 1290, 1021, 901, 751, 699 cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₁₆NO [M + H – N₂]⁺: 238.1242, found 238.1232.




N-(2-(1-Hydroxy-2-arylcyclobutyl)phenyl)aniline s3q. Method A was followed using 0.500 g of **s5f** (1.20 mmol), 4 mL of HCl (4 M in dioxane) to give **s3q** as a brown solid (0.229 g, 60%) which was submitted to the next step without further characterization or purification.

o-Cyclobutanol aryl azide 10f. The general procedure was followed by using 0.321 g of aniline **s3q** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product, a yellow oil, as a mixture of atropisomers (0.240 g, 68%): R_f = 0.56 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.74 (dd, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.67 (dd, *J* = 7.5 Hz, 1.5 Hz, 0.23H), 7.59 (dd, *J* = 8.0 Hz, 1.5 Hz, 1.19H), 7.54 – 7.50 (m, 0.53H), 7.44 – 7.41 (m, 1.23H), 7.40 – 7.35 (m, 1.27H), 7.31 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.24 – 7.18 (m, 1H), 7.15 – 7.09 (m, 3H), 6.32 – 6.29 (m, 0.22H), 4.32 – 4.28 (m, 1H), 3.18 (t, *J* = 7.5 Hz, 0.46H), 3.10 (d, *J* = 2.0 Hz, 0.92H), 2.85 – 2.79 (m, 1H), 2.56 (quin, *J* = 10.0 Hz, 1H), 2.37 – 2.29 (m, 0.49H), 2.27 – 2.19 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 139.0 (C), 137.2 (C), 136.3 (C), 133.2 (CH), 132.6 (CH), 131.0 (C), 130.8 (CH), 130.4 (CH), 130.2 (CH), 128.8 (CH), 128.2 (CH), 128.1 (CH), 127.2 (CH), 126.8 (CH), 126.6 (CH), 125.9 (CH), 124.9 (CH), 124.8 (CH), 119.2 (C), 119.1 (CH), 118.7 (CH), 82.9 (C), 80.6 (C), 49.0 (CH), 38.7 (CH₂), 30.4 (CH₂), 28.4 (CH₂), 22.9 (CH₂) only visible peaks; ATR-FTIR (thin film): 3459, 2956, 2924, 2854, 2125, 2093, 1637, 1485, 1281, 751 cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₁₅NOBr [M + H – N₂]⁺: 316.0346, found 316.0337.




N-(2-(1-Hydroxycyclobutyl)phenyl)aniline s3r. Method A was followed using 0.500 g of **s5g** (1.66 mmol), 4 mL of HCl (4 M in dioxane) to give **s3r** as a brown solid (0.233 g, 70%) which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide 10g.** The general procedure was followed by using 0.297 g of aniline **s3r** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 hexanes:EtOAc) gave the product as a yellow oil, (0.120 g, 38%): R_f = 0.54 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.39 (m, 1H), 7.35 – 7.30 (m, 1H), 7.20 – 7.13 (m, 2H), 5.95 – 5.92 (m, 2H), 3.38 – 3.34 (m, 1H), 3.12 – 3.06 (m, 2H), 3.00 – 2.95 (m, 1H), 2.68 (s, 1H), 2.64 – 2.57 (m, 1H), 2.15 – 2.11 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 137.3 (C), 137.1 (C), 134.8 (CH), 132.9 (CH), 128.7 (CH), 127.0 (CH), 124.7 (CH), 119.0 (CH), 76.0 (C), 46.6 (CH), 41.3 (CH₂), 39.8 (CH), 33.5 (CH₂); ATR-FTIR (thin film): 3459, 3050, 2923, 2123.4, 2089, 1668, 1485, 1292, 1078, 750 cm⁻¹. HRMS (ESI) m/z calcd for C₁₃H₁₄NO [M + H – N₂]⁺: 200.1082, found 200.1075.



N-(2-(1-Hydroxycyclobutyl)phenyl)aniline s3s: The compound was prepared by using the procedure developed by Bali and co-workers.¹⁸ To a solution of 0.500 g of **s5'h** (2.12 mmol) in 8 mL of EtOH was added 4 mL of a 10% aq soln of NaOH. The resulting mixture was heated to reflux, and the reaction progress was monitored using TLC. Once the starting material was consumed, the reaction mixture was cooled to room temperature and concentrated *in vacuo*. The resulting mixture was diluted with water and extracted with 3 × 10 mL of EtOAc. The combined organic phases were washed with saturated brine, dried over MgSO₄, filtered and the filtrate was concentrated *in vacuo* to give **s3s** as a yellow solid (0.301 g, 70%) which was submitted to the next step without further characterization or purification.


***o*-Cyclobutanol aryl azide 10h.** The general procedure was followed by using 0.205 g of aniline **s3s** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (10:1 Hex:EtOAc) gave the product as a yellow oil, (0.150 g, 65%): R_f = 0.52 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.32 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.23 (dd, *J* = 8.0 Hz, 2.0 Hz, 1H), 7.18 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.12 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 3.15 (s, 1H), 3.06 – 3.01 (m, 1H), 2.99 – 2.95 (m, 1H), 2.32 – 2.27 (m, 1H), 2.22 (dd, *J* = 13.0 Hz, 6.5 Hz, 1H), 1.60 – 1.41 (m, 4H), 1.38 – 1.27 (m, 1H), 1.11 (dd, *J* = 12.5 Hz, 6.0 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 137.4 (C), 133.4 (C), 128.8 (CH), 127.4 (CH), 124.8 (CH), 118.4 (CH), 77.1 (C), 53.1 (CH), 34.2 (CH₂), 32.8 (CH), 32.4 (CH₂), 28.6 (CH₂), 24.8 (CH₂); ATR-FTIR (thin film): 3400, 2944, 2853, 2123, 2085, 1484, 1446, 1277, 1022, 752 cm⁻¹. HRMS (ESI) m/z calcd for C₁₃H₁₆NO [M + H – N₂]⁺: 202.1229, found 202.1232.



N-(2-(1-Hydroxycyclobutyl)phenyl)aniline s3t. Method A was followed using 0.150 g of **s5i** (0.43 mmol), 2 mL of HCl (4 M in dioxane) to give **s3t** as a brown solid (0.063 g, 60%) which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide 10i.** The general procedure was followed using 0.248 g of aniline **s3t** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (20:1 Hex:EtOAc) gave the product as a yellow oil, (0.164 g, 60%): R_f = 0.54 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.45 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.32 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.20 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.14 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 3.07 (s, 1H), 2.82 – 2.77 (m, 1H), 2.49 – 2.44 (m, 1H), 2.01 – 1.74 (m, 6H), 1.56 – 1.46 (m, 4H), 1.39 – 1.19 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 137.3 (C), 134.0 (C), 128.7 (CH), 127.6 (CH), 125.0 (CH), 118.1 (CH), 79.1 (C), 54.0 (CH), 35.3 (CH₂), 32.9 (CH), 31.1 (CH₂), 28.9 (CH₂), 27.7 (CH₂), 26.1 (CH₂), 25.9 (CH₂), 25.2

(CH₂); ATR-FTIR (thin film): 2918, 2849, 2124, 1623, 1485, 1464, 1445, 1277, 1156, 1051, cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₂₀NO [M - H - N₂]⁺: 242.1536, found 242.1545.



N-(2-(1-Hydroxycyclobutyl)phenyl)aniline s3u. Method A was followed using 0.150 g of **s5i** (0.43 mmol), 2 mL of HCl (4 M in dioxane) to give **s3u** as a yellow solid (0.074 g, 70%) which was submitted to the next step without further characterization or purification.

***o*-Cyclobutanol aryl azide 10j.** The general procedure was followed using 0.250 g of aniline **s3u** (1.01 mmol), 0.480 mL of *t*-BuONO (4.04 mmol), 0.400 mL of Me₃SiN₃ (3.03 mmol) in 5.0 mL of MeCN. Purification by MPLC (20:1 Hex:EtOAc) gave the product as a yellow oil, (0.182 g, 66%): R_f = 0.55 (5:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.31 (dt, *J* = 8.0 Hz, 2.0 Hz, 1H), 7.19 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.16 – 7.11 (m, 2H), 3.38 (br s, 1H), 2.89 – 2.80 (m, 1H), 2.56 – 2.51 (m, 1H), 2.28 – 2.18 (m, 2H), 1.47 – 1.40 (m, 1H), 1.33 – 1.19 (m, 4H), 1.14 – 1.05 (m, 2H), 0.92 (t, *J* = 7.0 Hz, 3H), 0.87 – 0.81 (m, 1H), 0.78 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 137.4 (C), 134.2 (C), 128.7 (CH), 127.6 (CH), 124.9 (CH), 118.1 (CH), 78.2 (C), 51.0 (CH), 35.2 (CH₂), 32.8 (CH₂), 32.7 (CH), 29.6 (CH₂), 21.7 (CH₂), 20.6 (CH₂), 14.4 (CH₃), 14.3 (CH₃); ATR-FTIR (thin film): cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₂₂N [M – H – N₂O]⁺: 228.1744, found 228.1752.

III. Rh₂(II)-Catalyzed Benzazepine-2-one Formation

A. General Procedure for the Screening of Reaction Conditions




To a 10 mL Schlenk tube, under a nitrogen atmosphere, was added 0.10 mmol of azide followed by the metal salt (1 – 5 mol %) in 1.0 mL of solvent. The Schlenk tube was sealed and heated for 16 h. The reaction mixture was then cooled to room temperature and filtered through a pad of silica gel. The filtrate was concentrated *in vacuo*, and the crude mixture was analyzed using ^1H NMR spectroscopy using CH_2Br_2 as an internal standard.

Table s1. Screen of catalyst, catalyst loading, solvent and reaction temperature.

Entry	catalyst	mol %	solvent	T (°C)	9a yield, % ^a
1	PhMe	130	trace
2	Rh ₂ (O ₂ CCH ₃) ₄	5	PhMe	100	24
3	Rh ₂ (O ₂ CC ₇ H ₁₅) ₄	5	PhMe	100	15
4	Rh ₂ (O ₂ CCF ₃) ₄	5	PhMe	100	47
5	Rh ₂ (O ₂ CC ₃ F ₇) ₄	5	PhMe	100	66
6	Rh ₂ (esp) ₂	5	PhMe	100	80
7	Rh ₂ (esp) ₂	5	PhMe	120	71
8	Rh ₂ (esp) ₂	1	PhMe	120	82
9	RuBr ₃ •nH ₂ O	1	PhMe	120	23
10	Co(TPP)	5	PhMe	120	trace
11	[Ir(COD)(OMe)] ₂	5	PhMe	120	23
12	FeBr ₂	20	PhMe	120	...
13	FeBr ₂	30	CH ₂ Cl ₂	40	...
14	FeBr ₃	20	PhMe	120	...
15	FeBr ₃	30	CH ₂ Cl ₂	40	...

^a As determined using ¹H NMR spectroscopy using CH₂Br₂ as the internal standard.

B. Optimized Procedure



To a 10 mL Schlenk tube, under a nitrogen atmosphere, was added 0.10 mmol of azide followed by 0.001 mmol of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. The Schlenk tube was sealed and heated at 120 °C for 16 h. The reaction mixture was then cooled to room temperature and filtered through a pad of silica gel. The filtrate was concentrated *in vacuo*, and the crude mixture was purified by MPLC (7:1 – 3:1 hexanes:EtOAc) to afford the benzazepinone product.

C. Characterization Data for Benzazepine-2-one




Benzazepine-2-one 9a.¹⁹ The optimized procedure was followed using 0.019 g of azide **8a** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.0129 g, 80%). The spectral data of **9a** matched that reported by Chen and Gilman:¹⁹ ¹H NMR (500 MHz, CDCl₃) δ 7.55 (s, 1H), 7.26 – 7.22 (m, 2H), 7.14 (td, *J* = 7.5 Hz, 1.0 Hz, 1H), 6.97 (d, *J* = 7.5 Hz, 1H), 2.81 (t, *J* = 7.5 Hz, 2H), 2.36 (t, *J* = 7.5 Hz, 2H), 2.24 (quin, *J* = 7.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 175.0 (C), 137.7 (C), 134.4 (C), 129.9 (CH), 127.5 (CH), 125.8 (CH), 121.8 (CH), 32.7 (CH₂), 30.4 (CH₂), 28.4 (CH₂); ATR-FTIR (thin film): 3184, 3061,


2934, 1656, 1490, 1383, 1155, 787 cm^{-1} . The diastereomeric identity of the product was confirmed using X-Ray crystallography.²⁰




Benzazepine-2-one 9b.²¹ The optimized procedure was followed using 0.030 g of azide **s8b** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded product as an orange solid (0.0205 g, 80%). The spectral data of **9b** matched that reported by Crosby and co-workers:²¹ ¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 6.92 (d, *J* = 8.0 Hz, 1H), 6.76 – 6.74 (m, 1H), 6.52 (d, *J* = 2.0 Hz, 1H), 3.79 (s, 3H), 2.76 (t, *J* = 7.0 Hz, 2H), 2.32 (t, *J* = 7.0 Hz, 2H), 2.21 (quin, *J* = 7.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 175.0 (C), 159.0 (C), 138.5 (C), 130.6 (CH), 126.5 (C), 111.0 (CH), 107.8 (CH), 55.5 (CH₃), 32.8 (CH₂), 29.5 (CH₂), 28.6 (CH₂); ATR-FTIR (thin film): 3172, 2935, 1661, 1621, 1498, 1381, 1282, 1164, 1050, 890, 737 cm^{-1} .



Benzazepine-2-one 9c.²² The optimized procedure was followed using 0.029 g of azide **8c** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a white solid (0.016 g, 91%). Benzazepinone **9c** was previously reported by Huanming and co-workers:²² ¹H NMR (500 MHz, CDCl₃) δ 7.50 (br s, 1H), 7.0 (d, *J* = 5.5 Hz, 2H), 6.86 – 6.85 (m, 1H), 2.76 (t, *J* = 7.0 Hz, 2H), 2.36 – 2.33 (m, 5H), 2.21 (quin, *J* = 7.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 175.0 (C), 136.0 (C), 135.1 (C), 134.2 (C), 130.5 (CH), 128.0 (CH), 121.7 (CH), 32.7 (CH₂), 30.3 (CH₂), 28.4 (CH₂), 20.9 (CH₃); ATR-FTIR (thin film): 3178, 3041, 2933, 1656, 1504, 1386, 1160, 825 cm^{-1} .




Benzazepine-2-one 9d.²³ The optimized procedure was followed using 0.026 g of azide **8d** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a white solid (0.0169 g, 74%). Benzazepinone **9d** was previously reported by Hoyt and co-workers:²³ ¹H NMR (500 MHz, CDCl₃) δ 8.37 (s, 1H), 7.50 (d, *J* = 7.5 Hz, 2H), 7.09 (d, *J* = 8.0 Hz, 1H), 2.86 (t, *J* = 7.0 Hz, 2H), 2.40 (t, *J* = 7.5 Hz, 2H), 2.28 (quin, *J* = 8.0 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 175.1 (C), 141.1 (C), 134.7 (C), 127.6 (q, *J*_{CF} = 32.1 Hz, C), 127.1 (q, *J*_{CF} = 4.5 Hz, CH), 126.1 (q, *J*_{CF} = 269.4 Hz, C), 124.7 (q, *J*_{CF} = 3.6 Hz, CH), 121.8 (CH), 32.9 (CH₂), 30.5 (CH₂), 28.2 (CH₂); ¹⁹F NMR (282 MHz, CDCl₃) δ -62.6; ATR-FTIR (thin film): 3186, 2949, 1670, 1348, 1259, 1158, 1124, 1078, 932, 846 cm^{-1} .




Benzazepine-2-one 9e.²³ The optimized procedure was followed using 0.027 g of azide **8e** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.0174 g, 71%). Benzazepinone **9e** was previously reported by Hoyt and co-workers:²³ ¹H NMR (500 MHz,


CDCl_3) δ 8.35 (s, 1H), 7.10 – 7.09 (m, 2H), 7.03 – 7.01 (m, 1H), 2.81 (t, J = 7.5 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 2.25 (quin, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.1 (C), 146.4 (C), 136.5 (C), 136.2 (C), 123.0 (CH), 122.5 (CH), 120.5 (q, J_{CF} = 255.2 Hz, C), 120.0 (CH), 32.7 (CH₂), 30.5 (CH₂), 28.1 (CH₂); ^{19}F NMR (282 MHz, CDCl_3) δ -58.4; ATR-FTIR (thin film): 3170, 3074, 2943, 1683, 1496, 1380, 1283, 1231, 1205, 1165, 894, 814, 738 cm^{-1} .




Benzazepine-2-one 9f.²⁴ The optimized procedure was followed using 0.030 g of azide **8f** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded product as a brown solid (0.0229 g, 85%). Benzazepinone **9f** was previously reported by Takashi and co-workers:²⁴ ^1H NMR (500 MHz, CDCl_3) δ 7.37 (s, 1H), 7.11 (d, J = 8.5 Hz, 1H), 6.69 (dd, J = 8.0 Hz, 2.5 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 3.79 (s, 3H), 2.74 (t, J = 7.5 Hz, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.19 (quin, J = 7.0 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.3 (C), 157.4 (C), 135.9 (C), 130.8 (C), 123.1 (CH), 115.2 (CH), 112.2 (CH), 55.5 (CH₃), 32.5 (CH₂), 30.5 (CH₂), 28.2 (CH₂); ATR-FTIR (thin film): 3209, 2935, 1667, 1615, 1509, 1378, 1279, 1162, 1038, 858 cm^{-1} .



Benzazepine-2-one 9g.²⁵ The optimized procedure was followed using 0.020 g of azide **8g** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded product as a light orange solid (0.0136 g, 80%). Benzazepinone **9g** was previously reported by Huisgen:²⁵ R_f = 0.56 (1:1 hexanes:EtOAc); mp = 152 – 154 $^\circ\text{C}$; ^1H NMR (500 MHz, CDCl_3) δ 7.76 (s, 1H), 7.10 (d, J = 7.5 Hz, 1H), 6.94 (d, J = 7.0 Hz, 1H), 6.80 (s, 1H), 2.76 (t, J = 7.5 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 2.33 (s, 3H), 2.21 (quin, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.3 (C), 137.6 (C), 137.4 (C), 131.2 (C), 129.7 (CH), 126.4 (CH), 122.4 (CH), 32.8 (CH₂), 29.9 (CH₂), 28.5 (CH₂), 21.0 (CH₃); ATR-FTIR (thin film): 3172, 3077, 2940, 1684, 1662, 1512, 1383, 1159, 799 cm^{-1} .




Benzazepine-2-one 9h.²⁶ The optimized procedure was followed using 0.021 g of azide **8h** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.0136 g, 78%). Benzazepinone **9h** was previously reported by Altenbach and co-workers:²⁶ ^1H NMR (500 MHz, CDCl_3) δ 8.22 (s, 1H), 7.16 (dd, J = 8.0 Hz, 6.0 Hz, 1H), 6.83 (dt, J = 8.0 Hz, 2.5 Hz, 1H), 6.73 (dd, J = 9.0 Hz, 2.5 Hz, 1H), 2.27 (t, J_{CF} = 7.5 Hz, 2H), 2.37 (t, J = 7.5 Hz, 2H), 2.20 (quin, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.3 (C), 161.8 (d, J_{CF} = 244.5 Hz, C), 139.1 (d, J = 8.9 Hz, C), 130.9 (d, J_{CF} = 9.3 Hz, CH), 129.9 (C), 112.3 (d, J_{CF} = 20.2 Hz, CH), 109.1 (d, J_{CF} = 23.7 Hz, CH), 32.8 (CH₂), 29.7 (CH₂), 28.5 (CH₂); ^{19}F NMR (282 MHz, CDCl_3) δ -115.3; ATR-FTIR (thin film): 3187, 3102, 2951, 1663, 1605, 1507, 1483, 1260, 1161, 1151, 998, 834, 705 cm^{-1} .



Benzazepine-2-one 9i. The optimized procedure was followed using 0.026 g of azide **8i** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a white solid (0.0197 g, 86%): R_f = 0.30 (1:1 hexanes:EtOAc); mp = 146 – 148 $^\circ\text{C}$; ^1H NMR (500 MHz, CDCl_3) δ 8.48 (s,


1H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.34 (d, $J = 8.0$ Hz, 1H), 7.26 (s, 1H), 2.87 (t, $J = 7.0$ Hz, 2H), 2.38 (t, $J = 7.0$ Hz, 2H), 2.27 (quin, $J = 7.0$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.0 (C), 138.4 (C), 138.3 (C), 130.5 (CH), 130.1 (q, $J_{CF} = 32.8$ Hz, C), 123.7 (q, $J_{CF} = 270.3$ Hz, C), 122.4 (q, $J_{CF} = 3.8$ Hz, CH), 118.7 (q, $J_{CF} = 3.8$ Hz, CH), 32.7 (CH₂), 30.4 (CH₂), 28.2 (CH₂); ^{19}F NMR (282 MHz, CDCl_3) δ -62.9; ATR-FTIR (thin film): 3190, 2925, 1675, 1327, 1166, 1115, 1076, 987, 828, 672 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{11}\text{NOF}_3$ [M + H]⁺: 230.0794, found 230.0793.




Benzazepine-2-one 9j. The optimized procedure was followed using 0.022 g of azide **8j** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded the product as a brown solid (0.0155 g, 80%), as a mixture of rotamers: $R_f = 0.48$ (1:1 hexanes:EtOAc); mp = 142 – 144 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.93 (s, 1H), 7.00 (d, $J = 8.0$ Hz, 1H), 6.68 (d, $J = 10.0$ Hz, 1H), 2.85 (t, $J = 7.0$ Hz, 0.32H), 2.73 (t, $J = 7.0$ Hz, 2H), 2.35 (t, $J = 7.0$ Hz, 2H), 2.26 – 2.17 (m, 5.38H); ^{13}C NMR (125 MHz, CDCl_3) δ 175.2 (C), 159.9 (d, $J_{CF} = 242.5$ Hz, C), 136.4 (d, $J_{CF} = 9.8$ Hz, C), 132.3 (d, $J_{CF} = 6.0$ Hz, CH), 129.7 (d, $J_{CF} = 2.9$ Hz, C), 129.0 (d, $J_{CF} = 5.9$ Hz, C), 121.9 (d, $J_{CF} = 16.5$ Hz, 116.9 (C), 108.9 (d, $J_{CF} = 23.4$ Hz, CH), 32.9 (CH₂), 32.8 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 28.5 (CH₂), 27.5 (CH₂), 14.6 (CH₃), 14.1 (CH₃); ^{19}F NMR (282 MHz, CDCl_3) δ -119.3; ATR-FTIR (thin film): 3192, 2951, 2869, 1667, 1625, 1509, 1495, 1376, 1102, 881, 759 cm^{-1} HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{13}\text{NOF}$ [M + H]⁺: 194.0983, found 194.0981.




Benzazepine-2-one 9k. The optimized procedure was followed using 0.022 g of azide **8k** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded product as a light orange solid (0.0142 g, 74%): $R_f = 0.14$ (5:1 hexanes:EtOAc); mp = 160 – 162 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.22 (s, 1H), 7.07 (t, $J = 7.5$ Hz, 1H), 6.80 (t, $J = 8.0$ Hz, 2H), 3.83 (s, 3H), 2.78 (t, $J = 7.5$ Hz, 2H), 2.37 (t, $J = 7.5$ Hz, 2H), 2.23 (quin, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 174.3 (C), 150.1 (C), 134.8 (C), 126.8 (C), 125.5 (CH), 121.7 (CH), 109.1 (CH), 55.6 (CH₃), 33.3 (CH₂), 30.4 (CH₂), 28.5 (CH₂); ATR-FTIR (thin film): 3198, 2968, 2935, 1652, 1602, 1455, 1288, 1084, 787, 771 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{14}\text{NO}_2$ [M + H]⁺: 192.1019, found 192.1025.




Quinolinone 11a.²⁷ The optimized procedure was followed using 0.018 g of azide **10a** (0.10 mmol) and 0.0080 g of $\text{Rh}_2(\text{esp})_2$ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (7:1 – 3:1 hexanes:EtOAc) afforded product as a white solid (0.0118 g, 80%). The spectral data of **11a** matched that reported by Liu and Hu:²⁷ ^1H NMR (500 MHz, CDCl_3) δ 7.66 (br s, 1H), 7.19 – 7.16 (m, 2H), 6.99 (t, $J = 8.0$ Hz, 1H), 6.74 (d, $J = 8.0$ Hz, 1H), 2.97 (t, $J = 7.5$ Hz, 2H), 2.64 (t, $J = 7.0$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.4 (C), 137.1 (C), 128.1 (CH), 127.5 (CH), 127.4 (C), 123.3 (CH), 115.2 (CH), 30.8 (CH₂), 25.4 (CH₂); ATR-FTIR (thin film): 3197, 2975, 2914, 1682, 1595, 1492, 1439, 1386, 1282, 1246, 1033, 817, 749 cm^{-1} .



Benzazepine-2-one 11b.²⁸ The optimized procedure was followed using 0.019 g of azide **10b** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 1:1 hexanes:EtOAc) afforded product as a white solid (0.0083 g, 51%). The spectral data of **10b** matched that reported by Ashweek and co-workers:²⁸ ¹H NMR (500 MHz, CDCl₃) δ 8.21 (br s, 1H), 7.29 (d, *J* = 8.0 Hz, 1H), 7.14 (d, *J* = 7.5 Hz, 1H), 7.06 (t, *J* = 7.0 Hz, 1H), 6.93 (d, *J* = 8.0 Hz, 1H), 4.74 (s, 2H), 4.58 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 173.2 (C), 135.8 (C), 129.2 (CH), 128.7 (C), 128.6 (CH), 123.8 (CH), 119.2 (CH), 73.5 (CH₂), 72.9 (CH₂); ATR-FTIR (thin film): 3192, 3058, 2992, 1657, 1592, 1495, 1447, 1402, 1133, 944, 839 cm⁻¹.



Benzazepine-2-one 11c. The optimized procedure was followed using 0.024 g of azide **10c** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a white solid (0.0143 g, 66 %): R_f = 0.29 (3:1 Hexane:EtOAc); mp = 178 – 180 °C. ¹H NMR (500 MHz, CDCl₃) δ 8.09 (br s, 1H), 7.24 – 7.19 (m, 2H), 7.10 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 6.95 (dd, *J* = 7.5 Hz, 1.0 Hz, 1H), 2.84 – 2.78 (m, 2H), 2.43 – 2.34 (m, 2H), 2.20 (quin, *J* = 7.0 Hz, 1H), 0.99 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 175.4 (C), 137.8 (C), 134.1 (C), 130.9 (CH), 127.3 (CH), 125.3 (CH), 121.2 (CH), 51.4 (CH), 34.8 (CH₂), 34.4 (C), 32.4 (CH₂), 27.7 (CH₃); ATR-FTIR (thin film): 3056, 2962, 2360, 1663, 1586, 1491, 1264, 733 cm⁻¹. HRMS (ESI) m/z calcd for C₁₄H₂₀NO [M + H]⁺: 218.1543, found 218.1545.



Benzazepine-2-one 11d.²⁹ The optimized procedure was followed using 0.025 g of azide **10d** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a white solid (0.0237 g, quantitative). The spectral data of **11d** matched that reported by Hudson and co-workers:²⁹ ¹H NMR (500 MHz, CDCl₃) δ 8.25 (br s, 1H), 7.33 – 7.28 (m, 5H), 7.24 – 7.21 (m, 2H), 7.17 (t, *J* = 7.0 Hz, 1H), 7.07 (d, *J* = 7.5 Hz, 1H), 3.71 (quin, *J* = 7.5 Hz, 1H), 3.20 (dd, *J* = 14.0 Hz, 7.0 Hz, 1H), 2.91 (dd, *J* = 13.5 Hz, 6.5 Hz, 1H), 2.69 – 2.62 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 174.1 (C), 145.0 (C), 137.4 (C), 133.0 (C), 130.7 (CH), 128.7 (CH), 127.8 (CH), 126.9 (CH), 126.8 (CH), 125.7 (CH), 121.8 (CH), 46.7 (CH), 39.6 (CH₂), 38.8 (CH₂); ATR-FTIR (thin film): 3195, 3059, 2918, 1664, 1584, 1492, 1380, 1158, 756 cm⁻¹.




Benzazepine-2-one 11e.³⁰ The optimized procedure was followed using 0.025 g of azide **10e** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a white solid (0.0161 g, 72%). The spectral data of **11e** matched that reported by Ikeda and co-workers:³⁰ ¹H NMR (500 MHz, CDCl₃) δ 7.44 (br s, 1H), 7.39 (t, *J* = 7.5 Hz, 2H), 7.32 – 7.26 (m, 3H), 7.21 (t, *J* = 8.0 Hz, 1H), 7.04 (t, *J* = 8.0 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 6.80 (d, *J* = 7.5 Hz, 1H), 4.44 – 4.39 (m, 1H), 2.63 – 2.45 (m, 4H); ¹³C NMR (125 MHz, CDCl₃)


δ 174.6 (C), 140.9 (C), 137.1 (C), 137.0 (C), 128.9 (CH), 128.8 (CH), 128.6 (CH), 127.3 (CH), 127.1 (CH), 125.8 (CH), 121.8 (CH), 45.1 (CH), 33.6 (CH₂), 32.7 (CH₂); ATR-FTIR (thin film): 3198, 3060, 2924, 1665, 1484, 1381, 759, 735 cm⁻¹.




Benzazepine-2-one 11f. The optimized procedure was followed using 0.034 g of azide **s8s** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a brown solid (0.0209 g, 66%). R_f = 0.27 (1:1 hexanes:EtOAc); mp = 160 – 162 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.59 (dd, J = 8.0 Hz, 1.5 Hz, 1H), 7.47 – 7.39 (m, 3H), 7.24 – 7.16 (m, 2H), 7.04 – 6.97 (m, 2H), 6.59 (d, J = 7.5 Hz, 1H), 4.79 – 4.73 (m, 1H), 2.57 – 2.49 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 174.3 (C), 140.2 (C), 137.2 (C), 135.6 (C), 133.6 (CH), 129.2 (CH), 128.6 (CH), 128.0 (CH), 127.9 (C), 127.4 (CH), 126.0 (CH), 125.9 (CH), 121.8 (CH), 44.3 (CH), 32.7 (CH₂), 32.6 (CH₂); ATR-FTIR (thin film): 3197, 3060, 2924, 1667, 1486, 1470, 1379, 757, 738 cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₁₅NOBr [M + H]⁺: 316.0331, found 316.0337.




Benzazepine-2-one 11g. The optimized procedure was followed using 0.032 g of azide **10g** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a brown solid (0.0175 g, 60%): R_f = 0.24 (1:1 hexanes:EtOAc); mp = 158 – 160 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.66 (br s, 1H), 7.27 – 7.22 (m, 2H), 7.13 (t, J = 7.0 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1H), 5.90 – 5.89 (m, 1H), 5.78 – 5.76 (m, 1H), 3.68 – 3.58 (m, 2H), 2.74 – 2.61 (m, 3H), 2.27 – 2.23 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.5 (C), 137.0 (C), 136.7 (C), 132.2 (CH), 131.4 (CH), 131.0 (CH), 127.6 (CH), 125.5 (CH), 122.9 (CH), 52.1 (CH), 45.2 (CH), 39.9 (CH₂), 37.8 (CH₂); ATR-FTIR (thin film): 3197, 3050, 2920, 1666, 1583, 1489, 1433, 1391, 1169, 752, 732, 706 cm⁻¹. HRMS (ESI) m/z calcd for C₁₃H₁₄NO [M + H]⁺: 200.1072, found 200.1075.



Benzazepine-2-one 11h. The optimized procedure was followed using 0.023 g of azide **10h** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a brown solid (0.0147 g, 73%): R_f = 0.12 (3:1 hexanes:EtOAc); mp = 164 – 166 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.89 (br s, 1H), 7.24 – 7.20 (m, 2H), 7.12 (dt, J = 7.5 Hz, 1.0 Hz, 1H), 6.96 (dd, J = 7.5 Hz, 1.0 Hz, 1H), 3.29 (q, J = 7.5 Hz, 1H), 2.91 – 2.83 (m, 1H), 2.52 (dd, J = 12.5 Hz, 7.5 Hz, 1H), 2.14 (dd, J = 12.5 Hz, 7.5 Hz, 1H), 2.05 – 1.96 (m, 2H), 1.95 – 1.85 (m, 2H), 1.67 – 1.57 (m, 1H), 1.57 – 1.49 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 175.2 (C), 137.1 (C), 136.0 (C), 129.6 (CH), 127.2 (CH), 125.4 (CH), 122.5 (CH), 46.3 (CH), 44.5 (CH), 38.4 (CH₂), 31.4 (CH₂), 31.3 (CH₂), 25.0 (CH₂); ATR-FTIR (thin film): cm⁻¹. HRMS (ESI) m/z calcd for C₁₃H₁₆NO [M + H]⁺: 202.1229, found 200.1232.



Benzazepine-2-one 11i. The optimized procedure was followed using 0.024 g of azide **10i** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a white solid (0.0205 g, 95%): R_f = 0.23 (1:1 hexanes:EtOAc); mp = 173 – 175 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.91 (br s, 1H), 7.30 (dd, J = 7.5 Hz, 1.5 Hz, 1H), 7.24 – 7.17 (m, 2H), 6.98 (dd, J = 7.5 Hz, 1.5 Hz, 1H), 3.10 – 3.05 (m, 1H), 2.89 – 2.82 (m, 1H), 2.33 – 2.29 (m, 1H), 2.19 – 2.11 (m, 1H), 1.91 (t, J = 12.0 Hz, 1H), 1.87 – 1.81 (m, 1H), 1.75 – 1.58 (m, 6H), 1.56 – 1.46 (m, 3H), 1.14 – 1.09 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 174.9 (C), 137.7 (C), 137.1 (C), 127.5 (CH), 126.9 (CH), 125.5 (CH), 121.7 (CH), 42.8 (CH), 42.3 (CH₂), 41.0 (CH), 29.7 (CH₂), 28.4 (CH₂), 28.3 (CH₂), 26.7 (CH₂), 26.4 (CH₂), 25.3 (CH₂); ATR-FTIR (thin film): 3191, 2918, 2853, 2359, 1667, 1582, 1481, 1443, 1373, 757, 730 cm⁻¹. HRMS (ESI) m/z calcd for C₁₆H₂₂NO [M + H]⁺: 244.1697, found 244.1701.




Benzazepine-2-one 11j. The optimized procedure was followed using 0.027 g of azide **10i** (0.10 mmol) and 0.0080 g of Rh₂(esp)₂ (1 mol %) in 1.0 mL of toluene. Purification by MPLC (5:1 – 3:1 hexanes:EtOAc) afforded product as a brown solid (0.0160 g, 65%): R_f = 0.27 (2:1 hexanes:EtOAc); mp = 170 – 172 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.00 (br s, 1H), 7.24 – 7.16 (m, 3H), 7.01 – 6.99 (m, 1H), 3.09 (q, J = 6.5 Hz, 1H), 2.54 – 2.42 (m, 2H), 1.83 – 1.64 (m, 3H), 1.48 – 1.41 (m, 1H), 1.33 – 1.21 (m, 3H), 1.13 – 1.04 (m, 1H), 0.93 (t, J = 7.5 Hz, 3H), 0.90 – 0.80 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 175.5 (C), 137.8 (C), 135.1 (C), 127.5 (CH), 126.8 (CH), 125.3 (CH), 121.8 (CH), 42.7 (CH), 41.8 (CH), 39.5 (CH₂), 31.3 (CH₂), 30.8 (CH₂), 20.8 (CH₂), 19.5 (CH₂), 14.4 (CH₃), 14.1 (CH₃); ATR-FTIR (thin film): 3196, 2955, 2929, 2870, 1665, 1378, 756 cm⁻¹. HRMS (EI) m/z calcd for C₁₆H₂₃NO: 245.17819, found 245.17797.

The diastereomeric identity of the product was confirmed using X-Ray crystallography.³¹


IV. Mechanistic Experiments

A. Synthesis of Mechanism Probes.


The *ortho*-cyclopentanol aryl azide was constructed following the sequence below (Scheme s2).



Scheme s2. Synthesis of *ortho*-cyclopentanol aryl azide.




Spiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2(1H)-one s6.³² To a cooled (0 °C) 3 M solution of *N*-Boc aniline (0.800 g, 4.14 mmol) in 1.4 mL of dry Et₂O under an inert atmosphere of argon was dropwise added 5.45 mL of a 1.9 M solution of *t*-butyl lithium in pentane using a syringe pump. After 3 h, a solution of the 0.550 mL of cyclopentanone (6.21 mmol) in 2.0 mL dry Et₂O was added dropwise. The resulting mixture was allowed to warm to rt. The reagents were quenched through the addition of a saturated aq soln of NH₄Cl. The resulting mixture was diluted with EtOAc. The two layers were separated, and the aqueous layer was extracted 3 additional times with EtOAc (3 × 5 mL). The combined organic extracts were washed with brine, dried over MgSO₄ and the filtrate concentrated under reduced pressure. The resulting residue was purified by MPLC (2:1 hexanes:EtOAc) to afford the product as a white solid (0.33 g, 40%). The spectral data of **s6** matched that reported by Puwen and Jeffrey:²⁶ ¹H NMR (500 MHz, CDCl₃) δ 9.39 (br s, 1H), 7.22 – 7.19 (m, 1H), 7.12 (d, *J* = 7.5 Hz, 1H), 7.03 (t, *J* = 7.5 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 2.37 – 2.31 (m, 2H), 2.11 – 1.99 (m, 4H), 1.88 – 1.82 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.4 (C), 134.8 (C), 128.8 (CH), 124.6 (C), 123.3 (CH), 122.9 (CH), 114.6 (CH), 93.2 (C), 39.7 (CH₂), 23.7 (CH₂); ATR-FTIR (thin film): 3096, 2927, 1702, 1596, 1493, 1372, 1262, 1047, 762 cm⁻¹.




1-(2-Aminophenyl) cyclopentanol s7. To a solution of 0.330 g of **s6** (1.63 mmol) in 6.0 mL of EtOH was added 3.0 mL of a 10% aq soln of NaOH. The resulting mixture was heated to reflux, and the reaction progress was monitored using TLC. Once the starting material was consumed, the reaction mixture was cooled to room temperature and concentrated *in vacuo*. The resulting mixture was diluted with water and extracted with 3 × 10 mL of EtOAc. The combined organic phases were washed with saturated brine, dried over MgSO₄, filtered and the filtrate was concentrated *in vacuo* to give **s7** as a yellow solid (0.230 g, 80%) which was submitted to the next step without further characterization or purification.

1-(2-Azidophenyl) cyclopentanol 18. To a cooled solution (0 °C) of 0.092 g of 1-(*o*-aminophenyl) cyclopentanol **s7** (0.52 mmol) in 2.6 mL of MeCN, was added dropwise 0.250 mL of *t*-BuONO (2.08 mmol) and 0.210 mL of Me₃SiN₃ (1.56 mmol). The resulting solution was warmed to room temperature. After 1.5 h, the reaction mixture was concentrated in vacuo. The residue was purified by MPLC (10:1 hexanes:EtOAc) to afford the product as a yellow oil (0.085 g, 80%): R_f = 0.70 (3:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.46 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 7.31 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 7.19 (dd, *J* = 8.0 Hz, 1.0 Hz, 1H), 7.11 (dt, *J* = 7.5 Hz, 1.5 Hz, 1H), 2.99 (s, 1H), 2.11 – 2.04 (m, 4H), 2.01 – 1.92 (m, 2H), 1.82 – 1.74 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 137.2 (C), 137.1 (C), 128.4 (CH), 126.6 (CH), 124.8 (CH), 118.9 (CH), 82.6 (C), 39.6 (CH₂), 23.5 (CH₂); ATR-FTIR (thin film): 3423, 2951, 2871, 2120, 2084, 1576, 1484, 1443, 1284, 1000, 750 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₃N₃ONa [M + Na]⁺: 226.0957, found 226.0959.




1-Azido-2-(1-methoxycyclobutyl)benzene 21a. A solution of azide alcohol **8a** (0.100 g, 0.53 mmol) in THF (2 mL) was added to a cold (– 50 °C) stirred suspension of 60% NaH (0.030 g, 0.78 mmol) in THF (3 mL). After stirring for 10 min, methyl iodide (0.050 mL, 0.78 mmol) was added. The mixture was allowed to warm to room temperature overnight and

the reactives were quenched through the addition of water. The resulting mixture was extracted with dichloromethane, dried over anhydrous magnesium sulfate, and the filtrate was concentrated *in vacuo*. The resulting residue was purified by MPLC (15:1 hexanes:EtOAc) to provide the compound as a yellow oil (0.054 g, 50%): $R_f = 0.66$ (5:1 hexanes:EtOAc); ^1H NMR (500 MHz, CDCl_3) δ 7.34 (t, $J = 7.5$ Hz, 1H), 7.29 (d, $J = 7.5$ Hz, 1H), 7.19 (d, $J = 8.0$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 2.93 (s, 3H), 2.54 – 2.42 (m, 4H), 2.10 – 2.01 (m, 1H), 1.72 – 1.64 (m, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 138.6 (C), 132.7 (C), 129.1 (CH), 129.0 (CH), 123.9 (CH), 119.2 (CH), 81.8 (C), 50.6 (CH_3), 32.4 (CH_2), 14.9 (CH_2); ATR-FTIR (thin film): 2983, 2940, 2819, 2121, 2085, 1485, 1443, 1295, 1130, 752 cm^{-1} . HRMS (ESI) m/z calcd for $\text{C}_{11}\text{H}_{13}\text{N}_3\text{ONa} [\text{M} + \text{Na}]^+$: 226.0956, found 226.0958.




(1-(2-Azidophenyl)cyclobutoxy)trimethylsilane 21b. To a cooled solution (0 °C) of 0.162 g of aryl azide **8a** (0.86 mmol) in 8 mL of CH₂Cl₂ under an Ar atmosphere was added 1.00 mL of 2,6-lutidine (8.60 mmol) followed by the dropwise addition of 0.780 mL of Me₃SiOTf (4.30 mmol). After 3 h, the reaction mixture was passed through a short silica gel column using Et₂O as the eluent, and the filtrate was concentrated *in vacuo*. The resulting residue was purified by MPLC (20:1 hexanes:EtOAc) to give the product as a yellow oil (0.170 g, 75%): R_f = 0.47 (10:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.43 (d, *J* = 8.0 Hz, 1H), 7.34 (t, *J* = 7.5 Hz, 1H), 7.19 (d, *J* = 7.5 Hz, 1H), 7.12 (t, *J* = 8.0 Hz, 1H), 2.67 – 2.62 (m, 2H), 2.46 – 2.40 (m, 2H), 1.95 – 1.87 (m, 1H), 1.53 – 1.43 (m, 1H), 0.12 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 139.2 (C), 135.3 (C), 128.9 (CH), 127.2 (CH), 124.1 (CH), 119.6 (CH), 77.6 (C), 37.3 (CH₂), 14.0 (CH₂), 1.3 (CH₃); ATR-FTIR (thin film): 2953, 2123, 2090, 1487, 1444, 1294, 1249, 1135, 987, 839 cm⁻¹. HRMS (ESI) m/z calcd for C₁₃H₁₉N₃OSiNa [M + Na]⁺: 284.1195, found 284.1196.


B. Mechanistic experiments



Tetrahydrocyclopenta indol-ol 20. To a 10 mL Schlenk tube, under a nitrogen atmosphere, was added 0.020 g of azide **18** (0.10 mmol) followed by 0.080 g of Rh₂(esp)₂ (0.001 mmol) in 1.0 mL of toluene. The Schlenk tube was sealed and heated at 120 °C for 16 h. The reaction mixture was then cooled to room temperature and filtered through a pad of silica gel. The filtrate was concentrated *in vacuo*, and the crude mixture was purified by MPLC (5:1 – 3:1 hexanes:EtOAc) to afford the product as a brown liquid (0.009 g, 51%): R_f = 0.18 (3:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.28 – 7.26 (m, 1H), 7.13 – 7.10 (m, 1H), 6.76 (t, J = 7.0 Hz, 1H), 6.60 (d, J = 7.5 Hz, 1H), 4.01 – 3.99 (m, 1H), 3.91 (br s, 1H), 2.15 – 2.04 (m, 4H), 1.81 – 1.76 (m, 1H), 1.69 – 1.64 (m, 1H), 1.59 – 1.48 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 150.9 (C), 132.7 (C), 129.6 (CH), 123.9 (CH), 118.8 (CH), 109.6 (CH), 90.7 (C), 71.2 (CH), 41.3 (CH₂), 35.6 (CH₂), 24.7 (CH₂); ATR-FTIR (thin film): 3243, 2946, 2923, 2854, 1713, 1606, 1464, 1314, 1295, 1067, 1056, 756 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₄NO [M + H]⁺: 176.1074, found 176.1075.



Methoxy-tetrahydrocyclobuta indole 22a. To a 10 mL Schlenk tube, under a nitrogen atmosphere, was added 0.020 g of azide **21a** (0.10 mmol) followed by 0.080 g of Rh₂(esp)₂ (0.001 mmol) in 1.0 mL of toluene. The Schlenk tube was sealed and heated at 120 °C for 16 h. The reaction mixture was then cooled to room temperature and filtered through a pad of silica gel. The filtrate was concentrated *in vacuo*, and the crude mixture was purified by MPLC (5:1 – 3:1 hexanes:EtOAc) to afford the product as a brown liquid (0.009 g, 52%): R_f = 0.41 (5:1 hexanes:EtOAc) ¹H NMR (500 MHz, CDCl₃) δ 7.31 – 7.29 (m, 1H), 7.19 (dt, *J* = 7.5 Hz, 1.0 Hz, 1H), 6.88 – 6.85 (dt, *J* = 7.5 Hz, 1H), 6.76 – 6.74 (m, 1H), 4.20 (t, *J* = 6.5 Hz, 1H), 4.03 (br s, 1H), 3.05 (s, 3H), 2.48 – 2.35 (m, 2H), 2.24 – 2.17 (m, 1H), 1.47 – 1.39 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 152.2 (C), 130.3 (C), 129.7 (CH), 125.1 (CH), 119.7 (CH), 111.9 (CH), 86.3 (C), 59.2 (CH₃), 51.2 (CH), 31.9 (CH₂), 22.5 (CH₂); ATR-FTIR (thin film): 3359, 2922, 2852, 1607, 1464, 1310, 1172, 746 cm⁻¹. HRMS (ESI) m/z calcd for C₁₁H₁₄NO [M + H]⁺: 176.1075, found 176.1075.



Trimethylsilyloxytetrahydrocyclobutaindole 22b. To a 10 mL Schlenk tube, under a nitrogen atmosphere, was added 0.026 g of azide **21b** (0.10 mmol) followed by 0.080 g of Rh₂(esp)₂ (0.001 mmol) in 1.0 mL of toluene. The Schlenk tube was sealed and heated at 120 °C for 16 h. The reaction mixture was then cooled to room temperature and filtered through a pad of silica gel. The filtrate was concentrated *in vacuo*, and the crude mixture was purified by MPLC using neutral alumina (15:1 hexanes:EtOAc) to afford the product as a brown liquid (0.012 g, 51%): R_f = 0.84 (10:1 hexanes:EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.32 (d, *J* = 7.5 Hz, 1H), 7.16 (t, *J* = 8.0 Hz, 1H), 6.82 (t, *J* = 7.0 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 1H), 4.09 (dd, *J* = 8.0 Hz, 1.5 Hz, 1H), 4.04 (br s, 1H), 2.45 (dd, *J* = 10.0 Hz, 7.0 Hz, 2H), 2.17 – 2.11 (m, 1H), 1.38 – 1.30 (m, 1H), – 0.04 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 151.0 (C), 134.4 (C), 129.4 (CH), 125.4 (CH), 119.5 (CH), 112.0 (CH), 82.4 (C), 63.7 (CH), 35.1 (CH₂), 22.2 (CH₂), 1.26 (CH₃); ATR-FTIR (thin film): 3368, 2953, 2360, 2124, 1608, 1478, 1465, 1250, 1168, 1128, 841 cm⁻¹. HRMS (EI) m/z calcd for C₁₃H₂₀NOSi [M + H]⁺: 234.1314, found 234.1314.


V. References


- Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. *Organometallics* **1996**, *15*, 1518.
 - Nanjo, T.; Yamamoto, S.; Tsukano, C.; Takemoto, Y. *Org. Lett.* **2013**, *15*, 3754.
 - Sarvari, H. M.; Shargi, H. *J. Org. Chem.* **2006**, *71*, 6652.
 - Ghalib, M.; Niaz, B.; Jones, G. P.; Heinicke, W. J. *Heteroatom. Chem.* **2013**, *24*, 452.
 - Curtin, L. M.; Michaelides, R. M.; Heyman, H. R.; Frey, R. R. Abbott Laboratories. US WO 2010144468, December A1 16, 2010.
 - Deprés, J.-P.; Navarro, B.; Greene, A. E. *Tetrahedron* **1989**, *45*, 2989.
 - Montaigne, R.; Ghosez, L. *Angew. Chem. Int. Ed. Engl.* **1983**, *7*, 221.
 - Snider, B. B.; Spindell, D. K. *J. Org. Chem.* **1980**, *45*, 5017.
 - Nicolaou, K. C.; Adsool, V. A.; Hale, C. R. H. *Org. Lett.* **2010**, *12*, 1552.
 - Fensome, A.; Harrison, D. D.; Winneker, R. C.; Zhang, P.; Kern, J. C.; Terefenko, E. A. Wyeth, John, and Brother Ltd. US 2004000230 A1, December 31, 2003.
 - Zhu, F. F.; Shen, Y. Y.; Wan, X.; Feng, Y. Y.; Xu, H. J. *Tetrahedron* **2012**, *68*, 4145.
 - Bogdanowicz, M. J.; Trost, B. M. *J. Am. Chem. Soc.* **1973**, *95*, 5321.


-
13. Dabrowski, A. J.; Moebius, D. C.; Wommack, J. A.; Kornahrens, A. F.; Kingsbury, S. J. *Org. Lett.* **2010**, *12*, 3598.
 14. Lee-Ruff, E.; Wells, D. *Nucleosides, Nucleotides Nucleic Acids.* **2008**, *27*, 484.
 15. (a) Barral, K.; Moorhouse, A. D.; Moses, J. E. *Org. Lett.* **2007**, *9*, 1809. (b) Zhang, F.; Moses, J. E. *Org. Lett.* **2009**, *11*, 1587.
 16. Trunk, M.; Egan, M. Boehringer Ingelheim International G.m.b.H. 2008 WO 2008023001 A1 February 28, 2008.
 17. (a) Han, G.; Tamaki, M.; Hruby, V. J. *J. Peptide Res.* **2001**, *58*, 338. (b) Chakrabarty, M.; Kundu, T.; Harigaya, Y. *Synth. Commun.* **2006**, *36*, 2069.
 18. Dhillon, K. S.; Balakumar, C.; Bali. A. *Med. Chem. Res.* **2012**, *21*, 3053.
 19. Chen, W.Y.; Gilman, N. W. *J. Heterocyclic Chem.* **1983**, *20*, 663.
 20. CCDC number 1525478
 21. Crosby, I. T.; Shin, J. K.; Capuano, B. *Aust. J. Chem.* **2010**, *63*, 211.
 22. Huanming, C.; Bo, L.; Zhongqiang, Z.; Wenjie, C.; Wanmei, C.; Qingsong, L.; Jianghui, W.; Peng, Z.; Zhaojian, J.; Guiping, Z.; Chunhua, G.; Hongju, G.; Gaolei, Z. Shanghai Simcere Pharmaceutical R&D Co., Ltd. Peop. Rep. China WO 2014048165 A1, April 3, 2014.
 23. Park, M.; London, C.; Hoyt, B. S.; *Tetrahedron Lett.* **2009**, *50*, 1911.
 24. Kiyoshi, T.; Seiichiro, T.; Yoshiteru, E.; Takashi, T. Fujisawa Pharmaceutical Co., Ltd. Japan WO 9915524 A1, April 1, 1999.
 25. Huisgen, R. *Justus Liebigs Ann. Chem.* **1951**, *574*, 171.
 26. Altenbach, R. J.; Khilevich, A.; Kolasa, T.; Rohde, J. J.; Bhatia, P. A.; Patel, M. V.; Searle, X. B.; Yang, F.; Bunnelle, W. H.; Tietje, K.; Bayburt, E. K.; Carroll, W. A.; Meyer, M. D.; Henry, R.; Buckner, S. A.; Kuk, J.; Daza, A. V.; Milicic, I. V.; Cain, J. C.; Kang, C. H.; Ireland, L. M.; Carr, T. L.; Miller, T. R.; Hancock, A. A.; Nakane, M.; Esbenshade, T. A.; Brune, M. E.; O'Neill, A. B.; Gauvin, D. M.; Katwala, S. P.; Holladay, M. W.; Brioni, J. D.; Sullivan, J. P. *J. Med. Chem.* **2004**, *47*, 3220.
 27. Liu, B.; Hu, L. *Bioorg. Med. Chem.* **2003**, *11*, 3889.
 28. Ashweek, N.; Chen, M.; Coon, T. R.; Ewing, T.; Jiang, W.; Moree, W.; Rowbottom, M.; Wade, W.; Zhao L.; Zhu, Y. F.; Yu, J.; Beaton, G. Neurocrine Biosciences, Inc. WO 2008124614 A1, October 16, 2008.
 29. Hudson, K.; Laing, N.; Lewis, P. AstraZeneca AB, US WO 2007104933 A1, September 20, 2007.
 30. Sato, T.; Ishida, S.; Ishibashi, H.; Ikeda, M. *J. Chem. Soc., Perkin Trans. 1*, **1991**, 353.
 31. CCDC 1525486.
 32. Puwen, Z.; Jeffrey, K. Wyeth, US WO 20050085470 A1, April 21, 2005.

V. Spectral Data


A.	Spectral Data for Formamides s1	s-36
B.	Spectral Data for <i>ortho</i> -Cyclobutanol Anilines s3	s-52
C.	Spectral Data for <i>ortho</i> -Cyclobutanol Carbamates s5	s-76
D.	Spectral Data for <i>ortho</i> -Cyclobutanol Aryl Azides 8 and 10	s-96
E.	Spectral Data for Benzazepine-2-ones 9 and 11	s-138
F.	Spectral Data for Mechanism Experiments.....	s-180










8.840
8.818
8.591
8.573
8.549
7.872
7.823
7.594
7.577
7.386
7.371












— 161.280
— 158.773

— 145.132
— 133.762
— 126.361
— 125.414
— 125.157
— 123.410
— 122.693
— 121.504
— 121.358
— 121.187
— 119.581
— 119.308
— 114.754
— 112.878








21.280
21.134




~161.494
~158.770


139.050
138.809
134.683
134.423
133.067
131.898
127.241
126.542
122.789
119.641
111.045
109.665









163.050
161.096
160.838
158.734
135.898
135.805
134.449
134.373
132.950
132.879
113.271
113.094
112.688
112.505
109.772
109.540
106.699
105.949
105.734






8.777
8.738
7.848
7.748
7.733
7.681
7.665
7.498
7.327
7.312
7.260
7.248






161.009
~158.924
135.463
134.219
132.900
131.153
130.881
126.645
~124.486
122.694
122.322
122.014
121.978
120.186
118.859
118.824
116.273
115.265











161.295
161.195
159.250
158.802
135.336
135.285
133.888
133.840
133.472
133.381
122.677
122.524
109.480
109.239
106.430
106.403
106.307
106.087

14.026
13.898




8.582
8.560
8.399
7.227
7.211
7.134
7.082
7.065
7.049
7.040
7.038
7.035
7.032
7.024
7.021
7.019
7.016
6.923
6.907
6.728
6.712
6.610
6.603
6.598
6.594
6.587
6.585
6.581
6.570
6.565
4.197
3.858
3.851







6.842
6.834
6.828
6.825
6.696
6.685
6.679
6.675
6.672
6.645
6.643
6.637
6.634
6.628
6.626
6.620
6.617
3.761
3.757
3.754
2.637
2.629
2.621
2.614
2.605
2.595
2.363
2.360
2.357
2.353
2.351
2.348
2.344
2.341
2.338
2.335
2.332
2.329
2.326
2.323
2.319
2.316
1.994
1.991
1.985
1.981
1.648
1.639
1.632




s3b







s3b





7.017
6.931
6.916
6.603
6.587
3.977
2.674
2.670
2.665
2.659
2.652
2.645
2.640
2.634
2.628
2.622
2.617
2.363
2.348
2.342
2.329
2.323
2.309
2.305
2.272
2.043
2.035
2.025
2.016
2.006
1.996
1.986
1.984
1.974
1.965
1.956
1.665
1.682
1.648
1.632
1.627
1.616
1.611
1.595




s3c





**s3c**

7.416	
7.342	
7.330	
7.326	
6.668	-2.653
6.652	-2.649
2.643	-2.636
2.632	-2.626
2.626	-2.618
2.610	-2.606
2.600	-2.368
2.353	-2.362
2.350	-2.347
2.334	-2.343
2.328	-2.324
2.315	-2.309
2.303	-2.022
2.041	-2.018
2.031	-2.013
2.009	-2.003
2.000	-2.000
1.994	-1.990
1.981	-1.972
1.962	-1.962
1.677	-1.677
1.661	-1.661
1.645	-1.645
1.639	-1.639
1.629	-1.629
1.622	-1.622
1.613	-1.613
1.590	-1.590





s3d







s3d




7.063	
7.057	
6.980	
6.977	
6.974	
6.972	
6.963	
6.960	
6.957	
6.955	
6.620	
6.602	
2.624	
2.620	
2.617	
2.614	
2.607	
2.603	
2.597	
2.588	
2.581	
2.576	
2.571	
2.366	
2.360	
2.351	
2.347	
2.344	
2.341	
2.332	
2.328	
2.325	
2.322	
2.312	
2.307	
2.018	
2.009	
2.006	
2.000	
1.996	
1.990	
1.987	
1.981	
1.978	
1.968	
1.959	
1.635	
1.629	
1.618	
1.612	
1.596	



s3e







s3e


Chemical shifts (δ) for the ^{13}C NMR spectrum of compound **s3e**:


Chemical Shift (δ)
-144.406
-140.627
128.978
123.761
121.732
121.564
119.703
118.835
117.674
116.968
-77.061
-35.012
-13.500









s3g





**s3g**

7.128	
7.116	
7.111	
7.099	
6.405	
6.400	
6.388	
6.383	
6.371	
6.366	
6.345	
6.340	
6.323	
6.318	
2.604	
2.601	
2.599	
2.594	
2.587	
2.584	
2.578	
2.569	
2.562	
2.557	
2.552	
2.324	
2.318	
2.309	
2.306	
2.303	
2.300	
2.291	
2.287	
2.284	
2.281	
2.271	
2.265	
1.976	
1.973	
1.967	
1.963	
1.958	
1.954	
1.949	
1.945	
1.936	
1.620	
1.604	
1.598	
1.588	
1.582	
1.566	



**s3h**


7.273	
7.257	
6.960	
6.944	
-4.396	
-2.639	
-2.634	
-2.629	
-2.622	
-2.613	
-2.604	
-2.596	
-2.587	
-2.365	
-2.359	
-2.350	
-2.346	
-2.340	
-2.331	
-2.325	
-2.321	
-2.311	
-2.306	
-2.025	
-2.019	
-2.015	
-2.006	
-2.003	
-1.997	
-1.993	
-1.987	
-1.984	
-1.978	
-1.974	
-1.965	
-1.956	
-1.946	
-1.654	
-1.638	
-1.622	
-1.616	
-1.605	
-1.600	
-1.589	
-1.583	
-1.567	




-13.524

-34.998


-145.991
-131.248
-131.011
-130.739
-130.484
-127.411
-125.698
-125.224
-123.062
-120.898
-114.072
-114.040
-114.007
-113.975
-112.954
-112.920
-112.889
-112.860
-77.147




s3i




6.977	
6.960	
6.858	
6.842	
6.825	
6.352	-4.135
6.330	-2.819
	-2.814
	-2.796
	-2.775
	-2.755
	-2.632
	-2.622
	-2.613
	-2.605
	-2.596
	-2.589
	-2.580
	-2.445
	-2.425
	-2.403
	-2.349
	-2.330
	-2.315
	-2.309
	-2.291
	-2.161
	-2.124
	-2.009
	-1.999
	-1.989
	-1.979
	-1.969
	-1.959
	-1.950
	-1.895
	-1.876
	-1.856
	-1.836
	-1.660
	-1.643
	-1.626
	-1.610
	-1.605
	-1.573
	-1.270
	-1.261
	-1.256
	-1.242





s3j









$\swarrow^{162.151}$
 $\nwarrow^{160.221}$
 $\swarrow^{145.004}$
 $\swarrow^{144.924}$
 $\int^{130.355}$
 $\sqrt{130.290}$
 $\swarrow^{128.168}$
 $\swarrow^{128.113}$
 $\swarrow^{124.017}$
 $\swarrow^{112.690}$
 $\swarrow^{112.552}$
 $\swarrow^{111.790}$
 $\swarrow^{103.489}$
 $\swarrow^{103.289}$
 -77.111
 $\nearrow^{37.081}$
 $\nearrow^{37.036}$
 $\nearrow^{35.268}$
 $\swarrow^{16.958}$
 $\swarrow^{13.766}$
 $\swarrow^{13.689}$







**s3h**

3.275
3.267
3.259
3.241
3.112
3.107
2.517
2.511
2.483
2.478
2.473
2.460
1.793
1.787
1.780
1.774
1.770
1.755
1.749
1.741
1.711
1.704
1.694
1.686
1.679
1.674
1.668
1.661
1.655
1.650
1.645
1.640
1.573
1.567
1.560
1.548
1.539
1.531
1.525
1.367
1.351
1.345
1.334
1.323
1.314
1.312
1.305
1.297
1.272
1.268
1.261







7.371	7.365	7.359	7.354	7.343	7.329	7.324	7.318	7.311	5.702	5.697	5.692	5.688	5.142	2.722	2.717	1.485	1.477	1.472	1.468	1.463	1.458	1.451	1.444	1.435	1.376	1.364	1.361	1.357	1.350	1.347	1.343	1.338	1.333	1.328	1.323	1.319	1.315	1.304	1.301	1.286	1.279	1.276	1.260	1.256	1.239	0.926	0.921	0.912	0.907	0.897	0.893
-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------



s8





s8

-171.643
-166.519


136.491
128.496
128.270
128.137
128.005


111.486
111.010

-65.487


48.408
47.288

37.803
37.623
34.179
32.101
30.939
29.990
21.976
21.272
20.737
14.212
11.151







s9




-212.027

-61.723


-50.175



 $\int^{32.326}$
 $\int^{27.398}$
 $\int^{26.444}$
 $\swarrow^{21.417}$
 $\swarrow^{21.225}$
 $\swarrow^{14.117}$
 $\swarrow^{14.049}$ **s9**

7.823	7.600
7.594	7.183
7.166	6.555
6.549	6.538
6.532	6.532
3.803	-2.592
-2.587	-2.581
-2.575	-2.563
-2.567	-2.556
-2.550	-2.539
-2.545	-2.395
-2.391	-2.367
-2.361	-2.349
-2.343	-2.335
-2.328	-2.343
-2.324	-2.335
-2.316	-2.349
-2.310	-2.367
-2.033	-2.361
-2.028	-2.391
-2.025	-2.395
-2.021	-2.545
-2.014	-2.563
-2.009	-2.575
-2.007	-2.587
-2.003	-2.592
-1.996	-2.592
-1.992	-2.592
-1.674	-2.592
-1.653	-2.592
-1.639	-2.592
-1.634	-2.592
-1.624	-2.592
-1.621	-2.592
-1.616	-2.592
-1.602	-2.592
-1.504	-2.592







s1'f







-1.472


**s5b**

**s5b**









8.012
7.498
7.485
7.473
7.470
7.351
7.347
7.343
7.331
7.317
7.314
7.302
7.288
7.284
7.280
7.270
7.237
7.234
7.223
7.219
7.212
7.209
7.205
7.203
7.196
7.112
7.100
7.097
7.085
7.082
7.119
7.113
7.103
7.101
7.098
7.094
7.085
7.079
7.017
7.002
2.847
2.806
2.662
2.562
2.557
2.542
2.537
2.518
2.529
1.523




s5d





7.996	
7.980	
7.932	
7.468	
7.465	
7.462	
7.452	
7.449	
7.446	
7.412	7.397
7.381	
7.312	
7.310	
7.306	
7.302	
7.295	
7.291	
7.288	
7.286	
7.282	
7.278	
7.274	
7.271	
7.070	
7.067	
7.055	
7.052	
7.039	
7.037	
4.180	
4.163	
2.529	
2.526	
2.523	
2.517	
2.513	
2.507	
2.505	
2.499	
2.494	
2.486	
2.474	
2.468	
2.272	
2.269	
2.264	
2.246	
2.075	
2.073	
1.515	





0.96
0.94
3.08
2.04
2.29
1.10

1.01


3.13
1.00
1.00

9.21








7.964
7.948
7.801
7.785
7.669
7.621
7.604
7.588
7.404
7.389
7.374
7.297
7.282
7.266
7.163
7.147
7.132
7.069
7.053
7.038
4.576
4.559
4.544
2.600
2.594
2.587
2.567
2.561
2.548
2.539
2.483
2.474
2.465
2.456
2.443
2.437
2.434
2.426
2.419
2.405
2.402
2.386
2.290
2.288
2.279
2.273
2.260
2.255
2.243
2.234
1.454




s5f






**s5f**


7.850
7.834
7.491
7.317
7.314
7.301
7.298
7.285
7.282
7.270
7.266
7.259
7.254
7.251
7.059
7.056
7.044
7.041
7.029
7.026
5.982
5.978
5.974
5.971
3.453
3.439
3.436
3.433
3.422
3.419
3.139
3.132
3.124
3.120
3.099
3.097
2.905
2.869
2.657
2.653
2.639
2.483
2.141
2.138
2.135
2.118
2.115
2.111
1.503




s5g
















7.884	
7.793	
7.354	
7.338	
7.335	
7.282	
7.278	
7.264	
7.261	
7.031	
7.028	
7.024	
7.013	
2.853	
2.144	
1.940	
1.932	
1.927	
1.923	
1.905	
1.900	
1.895	
1.863	
1.858	
1.845	
1.839	
1.834	
1.761	
1.755	
1.749	
1.737	
1.549	
1.545	
1.540	
1.533	
1.504	
1.500	
1.489	
1.482	
1.473	
1.466	
1.300	
1.280	
1.280	
1.263	
1.256	
1.246	
1.237	
1.230	





**s5i**


7.949	7.931
7.315	7.300
7.312	7.297
7.262	7.277
7.259	7.274
7.246	7.262
7.243	7.259
7.019	7.246
7.017	7.243
7.004	7.259
7.002	7.262
2.695	6.989
2.689	6.987
2.676	6.987
2.662	6.989
2.657	6.989
2.251	6.987
2.002	6.989
1.999	6.987
1.986	6.989
1.971	6.989
1.964	6.989
1.950	6.989
1.650	6.989
1.589	6.989
1.508	6.989
1.469	6.989
1.454	6.989
1.450	6.989
1.439	6.989
1.434	6.989
1.423	6.989
1.413	6.989
1.408	6.989
1.312	6.989
1.297	6.989
1.283	6.989
1.192	6.989
1.176	6.989
1.015	6.989
1.001	6.989
0.986	6.989
0.921	6.989
0.907	6.989
0.892	6.989





7.347	
7.344	
7.332	
7.329	
7.317	
7.314	
7.302	
7.299	
7.174	
7.172	
7.158	
7.156	
7.143	
7.140	
7.128	
7.125	
7.113	
7.110	
3.239	
2.575	
2.573	
2.562	
2.558	
2.556	
2.552	
2.550	
2.544	
2.539	
2.537	
2.532	
2.526	
2.519	
2.399	
2.397	
2.393	
2.387	
2.381	
2.375	
2.369	
2.362	
2.356	
2.344	
2.118	
2.114	
2.100	
2.096	
1.678	
1.674	
1.669	
1.666	
1.661	
1.656	




**8a**

✓137.372
✓136.202
✓128.747
✓126.367
✓124.717
✓118.790


-76.728

-35.218


-14.457





7.101	
7.083	
6.908	
6.902	
6.852	
6.846	
6.835	
6.829	
3.804	-3.182
3.176	-3.176
2.552	-2.552
2.549	-2.549
2.537	-2.537
2.532	-2.532
2.526	-2.526
2.524	-2.524
2.519	-2.519
2.511	-2.511
2.507	-2.507
2.500	-2.500
2.496	-2.496
2.494	-2.494
2.388	-2.388
2.381	-2.381
2.375	-2.375
2.369	-2.369
2.364	-2.364
2.357	-2.357
2.351	-2.351
2.350	-2.350
2.346	-2.346
2.344	-2.344
2.337	-2.337
2.334	-2.334
2.332	-2.332
2.110	-2.110
2.107	-2.107
2.103	-2.103
2.097	-2.097
2.089	-2.089
2.085	-2.085
1.690	-1.690
1.688	-1.688
1.680	-1.680
1.675	-1.675
1.673	-1.673
1.667	-1.667
1.663	-1.663
1.651	-1.651




8b





**8b**

7.145	7.137
7.122	7.118
7.078	7.062
2.577	3.094
2.570	2.564
2.558	2.552
2.546	2.539
2.534	2.526
2.521	2.395
2.388	2.382
2.376	2.370
2.364	2.357
2.345	2.345
2.154	2.141
2.135	2.132
2.128	2.123
2.118	2.113
2.105	2.101
2.088	2.083
2.070	2.070
1.719	1.707
1.696	1.701
1.689	1.684
1.678	1.668
1.672	1.661
1.655	1.650
1.638	1.638



8c




**8c**

135.946
134.458
134.456
129.176
127.082
118.692


-76.767

-35.202


-21.000
-14.449




7.590	7.586
7.571	7.268
7.259	7.252
3.063	2.592
2.587	2.579
2.574	2.568
2.561	2.554
2.549	2.542
2.536	2.423
2.417	2.412
2.405	2.399
2.393	2.386
2.373	2.380
2.369	2.373
2.195	2.190
2.186	2.181
2.177	2.172
2.168	2.163
2.159	2.154
2.150	2.145
2.141	2.136
1.747	1.741
1.736	1.730
1.725	1.719
1.712	1.708
1.701	1.696
1.690	




8d







8d




7.194	
7.189	
7.181	
7.177	
7.158	
3.141	
2.548	
2.542	
2.535	
2.530	
2.523	
2.517	
2.510	
2.505	
2.498	
2.492	
2.401	
2.395	
2.390	
2.383	
2.377	
2.371	
2.364	
2.358	
2.351	
2.346	
2.173	
2.160	
2.155	
2.151	
2.146	
2.142	
2.137	
2.133	
2.128	
2.124	
2.120	
2.115	
2.110	
2.106	
2.101	
1.723	
1.717	
1.712	
1.705	
1.700	
1.694	
1.688	
1.683	
1.676	
1.671	
1.665	




8e







8e




7.268	7.251
6.721	6.716
6.665	6.660
6.648	6.643
3.829	3.829
2.960	2.960
2.553	2.553
2.551	2.551
2.547	2.547
2.540	2.540
2.535	2.535
2.534	2.534
2.528	2.528
2.522	2.522
2.515	2.515
2.510	2.510
2.504	2.504
2.498	2.498
2.384	2.384
2.378	2.378
2.372	2.372
2.366	2.366
2.360	2.360
2.347	2.347
2.341	2.341
2.335	2.335
2.329	2.329
2.115	2.115
2.110	2.110
2.097	2.097
2.093	2.093
2.088	2.088
2.085	2.085
2.079	2.079
2.075	2.075
1.682	1.682
1.677	1.677
1.669	1.669
1.664	1.664
1.655	1.655
1.652	1.652
1.647	1.647
1.642	1.642
1.625	1.625




8f







8f




7.241	7.226
6.987	6.949
6.946	6.934
6.931	6.930
3.060	2.561
2.556	2.549
2.543	2.537
2.531	2.524
2.519	2.513
2.506	2.500
2.400	2.391
2.385	2.379
2.373	2.367
2.360	2.354
2.348	2.341
2.335	2.306
2.116	2.110
2.106	2.098
2.094	2.088
2.085	2.080
2.076	2.063
2.058	2.045
2.045	1.680
1.667	1.662
1.658	1.654
1.650	1.645
1.632	




8g







8g





7.302	7.285	7.272	6.891	6.886	6.873	6.868	6.829	6.824	6.813	6.808	6.796	6.791	3.025	2.539	2.534	2.527	2.522	2.520	2.515	2.509	2.503	2.501	2.497	2.490	2.483	2.380	2.374	2.368	2.362	2.356	2.350	2.343	2.337	2.331	2.325	2.132	2.119	2.115	2.110	2.106	2.101	2.097	1.687	1.675	1.670	1.665	1.663	1.658	1.653	1.641
-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------




8h




**8h**

7.460	7.389	7.384	7.381	7.375	7.375	7.363	7.358	7.353	7.351	7.348	7.343
7.443	7.389	7.384	7.381	7.375	7.375	7.363	7.358	7.353	7.351	7.348	7.343
2.576	2.563	2.563	2.558	2.558	2.551	2.545	2.545	2.538	2.533	2.533	2.526
3.148	2.576	2.563	2.563	2.558	2.551	2.545	2.545	2.538	2.533	2.533	2.526
2.519	2.419	2.413	2.407	2.400	2.394	2.388	2.382	2.375	2.369	2.363	2.363
2.519	2.419	2.413	2.407	2.400	2.394	2.388	2.382	2.375	2.369	2.363	2.363
2.173	2.169	2.164	2.160	2.155	2.151	2.147	2.142	2.138	2.133	2.128	2.124
2.173	2.169	2.164	2.160	2.155	2.151	2.147	2.142	2.138	2.133	2.128	2.124
2.115	1.735	1.723	1.717	1.712	1.706	1.701	1.695	1.688	1.683	1.677	1.671
2.115	1.735	1.723	1.717	1.712	1.706	1.701	1.695	1.688	1.683	1.677	1.671
1.717	1.712	1.706	1.701	1.695	1.688	1.683	1.677	1.671	1.666	1.671	1.666
1.717	1.712	1.706	1.701	1.695	1.688	1.683	1.677	1.671	1.666	1.671	1.666



8i




-14.396


-35.075

-76.457


139.716
138.434
131.538
131.274
131.011
130.747
126.976
126.714
124.546
122.383
121.577
121.542
121.512
121.481
115.679
115.648
115.618
115.587




8i




7.135	
6.848	
6.841	
6.839	
6.829	
6.823	
2.971	-2.543
2.537	-2.530
2.525	-2.523
2.518	-2.512
2.505	-2.500
2.493	-2.487
	-2.377
	-2.371
	-2.353
	-2.347
	-2.341
	-2.334
	-2.328
	-2.323
	-2.249
	-2.245
	-2.215
	-2.210
	-2.141
	-2.136
	-2.123
	-2.119
	-2.114
	-2.110
	-2.105
	-2.101
	-2.088
	-1.700
	-1.695
	-1.689
	-1.683
	-1.678
	-1.672
	-1.666
	-1.661
	-1.654
	-1.649




8j








8j



7.095	7.079
7.076	7.063
7.060	6.948
6.946	6.933
6.930	6.850
6.847	6.834
6.831	6.834
6.898	6.847
6.308	6.930
2.570	6.946
2.556	6.933
2.552	6.930
2.550	6.850
2.546	6.847
2.544	6.834
2.538	6.831
2.531	6.898
2.526	6.308
2.520	2.570
2.513	2.556
2.410	2.552
2.407	2.550
2.404	2.546
2.398	2.544
2.392	2.538
2.390	2.531
2.386	2.526
2.384	2.520
2.380	2.513
2.378	2.410
2.374	2.407
2.372	2.404
2.369	2.398
2.366	2.392
2.356	2.390
2.354	2.386
2.118	2.384
2.114	2.380
2.109	2.378
2.096	2.374
1.683	2.372
1.679	2.369
1.674	2.366
1.671	2.356
1.656	2.354
1.661	2.118





-154.441

-138.106


\ 125.308
\\ 125.127
\\ 118.118
- 111.230


-76.997

-56.104


-35.329



-14.469






10a





**10a**

**10b**

7.387
7.384
7.372
7.369
7.356
7.353
7.228
7.225
7.213
7.210
7.183
7.181
7.167
7.165
7.152
7.150
7.137
7.135
5.055
5.040
4.809
4.794


-3.623





**10b**




✓137.385
✓132.398
-129.855
~126.977
~125.081
~118.714

-82.753
-75.672







10c





7.595	7.579
7.419	7.404
7.364	7.361
7.350	7.346
7.336	7.330
7.319	7.326
7.304	7.300
7.286	7.270
7.260	7.247
7.232	7.220
7.206	7.190
7.168	7.153
7.138	4.022
4.005	3.987
3.613	3.107
3.091	3.086
3.068	3.072
2.997	2.919
2.913	2.901
2.894	2.884
2.878	2.657
2.644	2.638
2.631	2.618
2.612	2.606
2.592	2.587
2.569	




10d













10e






7.749	7.733	7.730	7.596	7.593	7.580	7.577	7.432	7.428	7.416	7.413	7.397	7.394	7.382	7.379	7.306	7.303	7.291	7.288	7.214	7.152	7.150	7.137	7.135	7.127	7.122	7.119	7.115	7.112	7.106	7.104	7.100	7.097	7.090	7.088	4.317	4.301	4.297	4.280	3.104	3.100	2.808	2.556	2.535	2.250	2.233	2.249	2.214
-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------





10f

7.406	
7.392	
7.386	
7.331	
7.327	
7.322	
7.312	
7.307	
7.200	-7.194
7.178	-7.184
7.161	-7.156
7.149	-7.146
7.132	-7.141
7.126	
5.948	
5.941	
5.938	
5.934	
5.929	
5.924	
3.360	
3.353	
3.341	
3.122	
3.110	
3.106	
3.100	
3.083	
3.077	
2.997	
2.992	
2.987	
2.963	
2.958	
2.953	
2.679	
2.626	
2.613	
2.609	
2.140	
2.136	
2.131	
2.121	
2.118	
2.103	
2.108	



10g




**10g**


137.266
137.107
134.826
132.937
128.731
126.990
124.665
118.977

-76.016


-46.561
41.349
39.772
-33.511





7.334	
7.322	7.319
7.307	7.304
7.294	7.231
7.219	7.215
7.183	7.180
7.167	7.164
7.138	7.140
7.125	7.123
7.110	7.108
3.150	3.035
3.031	3.018
2.971	2.964
2.287	2.295
2.277	2.270
2.234	2.221
1.550	1.525
1.538	1.515
1.504	1.501
1.487	1.482
1.485	1.473
1.464	1.470
1.446	1.460
1.442	1.451
1.438	1.426
1.426	1.382
1.382	1.352
1.352	1.119




10h








7.450	
7.447	
7.434	
7.431	
7.326	
7.323	
7.311	
7.308	
7.202	-7.200
7.187	-7.184
7.161	-7.159
7.146	-7.144
3.072	-2.795
7.131	-2.470
7.144	-2.466
7.159	-1.955
7.161	-1.932
7.184	-1.919
7.200	-1.908
7.311	-1.902
7.323	-1.895
7.326	-1.878
7.431	-1.856
7.434	-1.841
7.447	-1.833
7.450	-1.813
	-1.809
	-1.785
	-1.548
	-1.543
	-1.539
	-1.531
	-1.520
	-1.513
	-1.499
	-1.491
	-1.482
	-1.290
	-1.279
	-1.271
	-1.262
	-1.253
	-1.245
	-1.237






10i





**10i**



7.330	7.318
7.315	7.303
7.299	7.199
7.196	7.183
7.180	7.158
7.158	7.143
7.141	7.141
7.128	7.126
7.126	7.114
7.114	3.379
3.379	2.545
2.545	2.537
2.537	2.534
2.527	2.527
2.256	2.252
2.236	2.231
2.231	2.222
2.215	2.215
2.207	2.207
1.441	1.441
1.435	1.435
1.323	1.323
1.277	1.277
1.270	1.270
1.257	1.257
1.253	1.253
1.248	1.248
1.237	1.237
1.227	1.227
1.117	1.117
1.105	1.105
1.099	1.099
1.090	1.090
1.084	1.084
1.080	1.080
1.076	1.076
0.938	0.938
0.924	0.924
0.910	0.910
0.830	0.830
0.825	0.825
0.786	0.786
0.752	0.758










**9b**

**9b**


-175.286



-157.402


\ 135.913
\ 130.812
\ 123.080
/\ 115.204
/\ 112.199

-55.480

/ 32.529
-\ 30.532
\ 28.237








**9c**


-174.965

135.503
135.096
134.230
130.497
127.928
121.682


32.649
30.264
28.360
20.873









-175.061







**9e**



-175.086


-146.421

136.513
136.188
123.564
122.967
122.436
121.462
119.997
119.419
117.377


32.653
-30.443
28.114


**9f**

**9f**



9g






**9g**


-175.238



137.591
137.385
131.218
129.676
126.393
122.397


32.790
29.893
28.507
20.935




**9h**





**9i**







gi







**9j**


-14.054

 $\begin{array}{l} \diagup 32.722 \\ \diagdown 29.586 \\ \diagdown 28.463 \end{array}$
 $\begin{array}{l} -175.214 \\ \diagup 160.906 \\ \diagup 158.966 \\ \diagup 136.396 \\ \diagup 136.318 \\ \diagup 132.281 \\ \diagup 132.233 \\ \diagup 129.697 \\ \diagup 129.674 \\ \diagup 129.043 \\ \diagup 128.996 \\ \diagdown 121.968 \\ \diagdown 121.836 \\ \diagdown 108.974 \\ \diagdown 108.779 \end{array}$
**9j**

**9k**

**9k**


**11a**



**11a**

-171.470

-137.152
128.041
127.547
123.736
123.149
~115.272

-29.719
-25.372




**11b**



**11b**


-173.159


135.828
129.199
128.714
128.577
123.765
119.206

73.461
72.864











11d




**11d**

-174.141


144.967
137.838
132.993
130.667
128.725
127.830
126.854
126.799
125.730
121.830


~46.650
~39.615
~38.831







11e







7.607
7.604
7.591
7.588
7.468
7.459
7.455
7.443
7.439
7.425
7.422
7.410
7.408
7.237
7.225
7.222
7.210
7.206
7.194
7.190
7.179
7.175
7.024
7.009
6.996
6.594
4.789
4.778
4.770
4.753


2.568
2.559
2.554
2.549
2.538
2.527
2.518
2.511
2.508
2.487


**11f**








11g






7.890	7.239
7.236	7.229
7.225	7.221
7.214	7.211
7.211	7.199
7.195	7.141
7.139	7.127
7.124	7.124
7.111	7.109
6.967	6.951
6.964	6.949
3.290	3.290
3.271	3.271
2.872	2.862
2.534	2.524
2.499	2.499
2.159	2.159
2.144	2.144
2.134	2.134
2.119	2.119
2.021	2.021
2.018	2.018
2.007	2.007
2.002	2.002
1.992	1.992
1.984	1.984
1.977	1.977
1.914	1.914
1.905	1.905
1.901	1.901
1.894	1.894
1.890	1.890
1.885	1.885
1.882	1.882
1.879	1.879
1.869	1.869
1.606	1.606
1.549	1.549
1.525	1.525







7.913	7.313
7.310	7.298
7.295	7.225
7.222	7.210
7.210	7.207
7.207	7.201
7.201	7.198
7.198	7.186
7.186	7.183
7.183	6.991
6.991	6.988
6.988	6.976
6.976	6.973
6.973	2.307
2.307	2.304
2.304	2.294
2.294	2.290
2.290	2.142
2.142	2.138
2.138	1.938
1.938	1.914
1.914	1.891
1.891	1.730
1.730	1.721
1.721	1.718
1.718	1.714
1.714	1.710
1.710	1.700
1.700	1.693
1.693	1.692
1.692	1.683
1.683	1.670
1.670	1.665
1.665	1.648
1.648	1.642
1.642	1.635
1.635	1.631
1.631	1.625
1.625	1.610
1.610	1.534
1.534	1.530
1.530	1.524
1.524	1.514
1.514	1.507
1.507	1.497
1.497	1.101



11i




-174.847






\begin{array}{l} 137.679 \\ 137.077 \\ 127.494 \\ 126.845 \\ 125.531 \\ 121.660 \end{array}

\begin{array}{l} 42.800 \\ 42.285 \\ 40.949 \\ 29.724 \\ 28.359 \\ 28.264 \\ 26.655 \\ 26.352 \\ 25.327 \end{array}




7.998	7.232
7.222	7.218
7.205	7.195
7.192	7.181
7.008	6.995
6.991	6.995
3.095	3.095
3.081	3.081
2.512	2.502
2.466	2.442
2.462	2.428
2.424	2.424
1.826	1.803
1.780	1.760
1.773	1.744
1.695	1.680
1.669	1.665
1.450	1.444
1.438	1.431
1.312	1.312
1.297	1.297
1.282	1.266
1.236	1.236
1.105	1.098
1.084	1.084
0.946	0.946
0.931	0.931
0.895	0.895
0.868	0.853
0.859	0.859
0.817	0.817







7.463	
7.447	
7.444	
7.328	
7.325	
7.312	
7.309	
7.297	
7.294	
7.197	
7.195	
7.181	
7.179	
7.130	
7.128	
7.115	
7.112	
7.100	
7.097	
2.987	
2.106	
2.102	
2.099	
2.095	
2.088	
2.083	
2.076	
2.071	
2.044	
1.988	
1.984	
1.979	
1.974	
1.968	
1.964	
1.960	
1.956	
1.952	
1.944	
1.936	
1.932	
1.807	
1.799	
1.793	
1.784	
1.779	
1.774	
1.771	
1.764	
1.759	
1.755	



18




**18**

137.193
137.139
128.350
126.580
124.795
118.877


-82.589

-39.612


-23.485



7.353	
7.338	
7.323	
7.290	
7.275	
7.198	
7.182	
7.132	-2.928
7.117	-2.538
7.102	-2.525
7.250	-2.520
7.214	-2.514
7.206	-2.506
7.200	-2.500
7.206	-2.496
7.202	-2.482
7.200	-2.470
7.200	-2.459
7.200	-2.453
7.200	-2.450
7.200	-2.446
7.200	-2.441
7.200	-2.439
7.200	-2.434
7.200	-2.427
7.200	-2.421
7.200	-2.416
7.200	-2.082
7.200	-2.079
7.200	-2.075
7.200	-2.065
7.200	-2.061
7.200	-2.057
7.200	-2.050
7.200	-2.046
7.200	-2.042
7.200	-2.028
7.200	-2.025
7.200	-1.705
7.200	-1.698
7.200	-1.694
7.200	-1.687
7.200	-1.682
7.200	-1.676
7.200	-1.670
7.200	-1.665
7.200	-1.658
7.200	-1.654
7.200	-1.648



21a




✓138.621
✓132.729
<129.055
<128.947
~123.922
~119.214

-81.775


-50.607



-32.384

-14.926





21a







21b





7.279	
7.264	
7.260	
7.128	
7.126	
7.112	
7.098	
7.095	-7.095
6.776	-6.776
6.761	-6.761
6.747	-6.747
6.602	-6.602
6.587	-6.587
4.007	-4.007
4.002	-4.002
3.993	-3.993
3.989	-3.989
2.151	-2.151
2.147	-2.147
2.139	-2.139
2.133	-2.133
2.126	-2.126
2.105	-2.105
2.100	-2.100
2.092	-2.092
2.087	-2.087
2.084	-2.084
2.079	-2.079
2.074	-2.074
2.071	-2.071
2.067	-2.067
2.060	-2.060
2.054	-2.054
2.045	-2.045
2.040	-2.040
1.795	-1.795
1.789	-1.789
1.783	-1.783
1.777	-1.777
1.770	-1.770
1.677	-1.677
1.671	-1.671
1.664	-1.664
1.653	-1.653
1.574	-1.574
1.562	-1.562
1.554	-1.554
1.549	-1.549
1.541	-1.541
1.536	-1.536
1.529	-1.529
1.516	-1.516




20






**20**

7.311	
7.309	
7.297	
7.296	7.294
7.293	7.205
7.202	7.190
7.187	7.172
7.174	7.172
6.880	6.880
6.877	6.865
6.850	6.863
6.848	6.850
6.761	6.760
6.758	6.746
6.744	6.742
4.212	4.212
4.198	4.185
4.185	3.053
2.465	2.462
2.462	2.442
2.440	2.420
2.420	2.397
2.395	2.395
2.385	2.383
2.383	2.379
2.379	2.374
2.217	2.208
2.208	2.192
2.192	2.155
2.155	1.447
1.447	1.435
1.435	1.428
1.428	1.423
1.423	1.411



22a







22a

-152.243
-130.323
-129.691
-125.112
-119.713
-111.904

-86.312
-59.215
-51.222
-31.876
-22.532



22b





22b

